0001051514-21-000018 | 10-K | XBRL Viewer

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2020	Mar. 17, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	STRATA Skin Sciences, Inc.
Entity Central Index Key	0001051514
Current Fiscal Year End Date	--12-31
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Address, State or Province	PA
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 23,624,112
Entity Common Stock, Shares Outstanding		33,801,045

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 10,604	$ 8,129
Restricted cash	7,508	7,500
Accounts receivable, net	2,944	4,386
Inventories	3,444	3,027
Prepaid expenses and other current assets	331	513
Total current assets	24,831	23,555
Property and equipment, net	5,529	5,369
Operating lease right-of-use assets	988	1,314
Intangible assets, net	6,345	7,955
Goodwill	8,803	8,803
Other assets	282	347
Total assets	46,778	47,343
Current liabilities:
Note payable	7,275	7,275
Current portion of long-term debt	1,478	0
Accounts payable	2,764	1,880
Other accrued liabilities	4,690	5,134
Deferred revenues	2,262	2,832
Current portion of operating lease liabilities	369	313
Total current liabilities	18,838	17,434
Long-term liabilities:
Long-term debt, net	1,050	0
Long-term operating lease liabilities, net	710	1,078
Deferred tax liability	254	0
Other liabilities	34	178
Total liabilities	20,886	18,690
Commitments and contingencies (see Note 11)
Stockholders' equity:
Series C Convertible Preferred Stock, $.10 par value, 10,000,000 shares authorized; 0 and 2,103 shares issued and outstanding as of December 31, 2020 and 2019, respectively	0	1
Common Stock, $.001 par value, 150,000,000 shares authorized; 33,801,045 and 32,932,273 shares issued and outstanding as of December 31, 2020 and 2019, respectively	34	33
Additional paid-in capital	244,831	243,180
Accumulated deficit	(218,973)	(214,561)
Total stockholders' equity	25,892	28,653
Total liabilities and stockholders' equity	$ 46,778	$ 47,343

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Stockholders' equity:
Series C Convertible Preferred Stock, par value (in dollars per share)	$ 0.10	$ 0.10
Series C Convertible Preferred Stock, shares authorized (in shares)	10,000,000	10,000,000
Series C Convertible Preferred Stock, shares issued (in shares)	0	2,103
Series C Convertible Preferred Stock, shares outstanding (in shares)	0	2,103
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock shares issued on exercise of options (in shares)	33,801,045	32,932,273
Common stock, shares outstanding (in shares)	33,801,045	32,932,273

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues, net	$ 23,090	$ 31,586
Cost of revenues	8,956	11,316
Gross profit	14,134	20,270
Operating expenses:
Engineering and product development	1,274	1,002
Selling and marketing	9,038	12,003
General and administrative	7,898	10,275
Total operating expenses	18,210	23,280
Loss from operations	(4,076)	(3,010)
Other (expense) income, net:
Interest expense, net	(61)	(515)
Loss on extinguishment of debt	0	(414)
Other (expense) income, net	(61)	(929)
Income (loss) before income taxes	(4,137)	(3,939)
Income tax (expense) benefit	(275)	149
Net loss	$ (4,412)	$ (3,790)
Loss per common share:
Basic (in dollars per share)	$ (0.13)	$ (0.11)
Diluted (in dollars per share)	$ (0.13)	$ (0.11)
Shares used in computing loss per common share:
Basic (in shares)	33,609,922	31,978,665
Diluted (in shares)	33,609,922	31,978,665
Loss per Series C Convertible Preferred share basic and diluted (in dollars per share)	$ (48.59)	$ (42.24)
Shares used in computing loss per basic and diluted Series C Convertible Preferred shares (in shares)	368	4,577
Series C Convertible Preferred Shares [Member]
Other (expense) income, net:
Loss attributable to each class	$ (18)	$ (193)
Common Shares [Member]
Other (expense) income, net:
Net loss	0	0
Loss attributable to each class	$ (4,394)	$ (3,597)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock [Member] Convertible Preferred Stock Series C [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Beginning balance at Dec. 31, 2018	$ 1	$ 30	$ 241,988	$ (210,771)	$ 31,248
Beginning balance (in shares) at Dec. 31, 2018	9,968	29,943,086
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 0	$ 0	1,195	0	1,195
Conversion of convertible preferred stock into common stock	$ 0	$ 3	(3)	0	0
Conversion of convertible preferred stock into common stock (in shares)	(7,865)	2,923,791
Exercise of stock options	$ 0	$ 0	0	0	0
Exercise of stock options (in shares)	0	36,410
Issuance of restricted stock	$ 0	$ 0	0	0	0
Issuance of restricted stock (in shares)	0	28,986
Net loss	$ 0	$ 0	0	(3,790)	(3,790)
Ending balance at Dec. 31, 2019	$ 1	$ 33	243,180	(214,561)	28,653
Ending balance (in shares) at Dec. 31, 2019	2,103	32,932,273
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 0	$ 0	1,633	0	1,633
Conversion of convertible preferred stock into common stock	$ (1)	$ 1	0	0	0
Conversion of convertible preferred stock into common stock (in shares)	(2,103)	782,089
Exercise of stock options	$ 0	$ 0	18	0	18
Exercise of stock options (in shares)	0	15,000
Issuance of restricted stock	$ 0	$ 0	0	0	0
Issuance of restricted stock (in shares)	0	71,683
Net loss	$ 0	$ 0	0	(4,412)	(4,412)
Ending balance at Dec. 31, 2020	$ 0	$ 34	$ 244,831	$ (218,973)	$ 25,892
Ending balance (in shares) at Dec. 31, 2020	0	33,801,045

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From Operating Activities:
Net loss	$ (4,412)	$ (3,790)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	3,585	4,503
Amortization of right-of-use assets	326	318
Provision for doubtful accounts	90	43
Impairment of lasers placed-in-service	24	30
Stock-based compensation	1,633	1,195
Deferred taxes	254	(111)
Amortization of deferred financing costs and debt discount	0	174
Changes in operating assets and liabilities:
Accounts receivable	1,352	(1,036)
Inventories	(417)	(233)
Prepaid expenses and other assets	247	104
Accounts payable	884	116
Other accrued liabilities	(444)	634
Other liabilities	(144)	(210)
Operating lease liabilities	(312)	(241)
Deferred revenues	(570)	733
Net cash provided by operating activities	2,096	2,229
Cash Flows From Investing Activities:
Lasers placed-in-service	(2,133)	(2,676)
Purchases of property and equipment	(26)	(115)
Net cash used in investing activities	(2,159)	(2,791)
Cash Flows From Financing Activities:
Proceeds from exercise of stock options	18	0
Repayments of long-term debt	0	(7,571)
Proceeds on notes payable	2,528	7,275
Net cash provided by (used in) financing activities	2,546	(296)
Net increase (decrease) in cash and cash equivalents and restricted cash	2,483	(858)
Cash and cash equivalents and restricted cash, beginning of period	15,629	16,487
Cash and cash equivalents and restricted cash, end of period	18,112	15,629
Cash and cash equivalents	10,604	8,129
Restricted cash	7,508	7,500
Supplemental information:
Cash paid for interest	211	766
Cash paid for income taxes	0	0
Lease liabilities from obtaining right of use assets	$ 0	$ 1,632

The Company

12 Months Ended

Dec. 31, 2020

The Company [Abstract]

The Company

Note 1

The Company:

Background

STRATA Skin Sciences (the “Company”) is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.

The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRAC excimer laser system first received clearance from the United States Food and Drug Administration (the “FDA”) in 2000. As of December 31, 2020, there were 832 XTRAC systems placed in dermatologists’ offices in the United States and 28 systems internationally under the Company’s recurring revenue business model. The XTRAC systems deployed under the recurring revenue model generate revenue on a per procedure basis or include a fixed payment over an agreed upon period with a capped number of treatments, which if exceeded, domestically, would incur additional fees. The per-procedure charge is inclusive of the use of the system and the services provided by the Company to the customer which includes system maintenance, and other services. The VTRAC Excimer Lamp system, offered in addition to the XTRAC system internationally, provides targeted therapeutic efficacy demonstrated by excimer technology with a lamp system.

In July 2019, the Company signed a direct distribution agreement with its Korean distributor for a combination of direct capital sales and recurring revenues for the country of South Korea.

In September 2020, the Company signed a direct distribution agreement with our Japanese distributor for a combination of direct capital sales and recurring revenue for the Country of Japan.

The Company has now introduced its Home by XTRAC™ business leveraging in-house resources including DTC advertising, in-house call center and its insurance reimbursement team to provide an at-home, insurance-reimbursed treatment option for patients with certain skin diseases that do not qualify for in-office treatments.

In February 2021, the Company signed an agreement with our Chinese distributor for a combination of direct capital sales and recurring revenues for the country of China.

In late 2019, there was an outbreak of a new strain of coronavirus (“COVID-19”) which became a global pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains, constrained work force participation and created significant volatility and disruption of financial markets. In addition, the pandemic lead to the suspension of elective procedures in the U.S. and to the temporary closure of many physician practices which are our primary customers. We do not know the extent of the impact on our customers including their potential for permanent closure. While many offices have reopened, the on-going impact of the COVID-19 pandemic on the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frames, will depend on future developments, including the duration and spread of the COVID-19 outbreak, continued restrictions on business operations and transport and the continued impact on worldwide economic and geopolitical conditions, all of which are uncertain and cannot be predicted.

Domestically, as the procedures in which the Company’s devices are used are elective in nature; and as social distancing, travel restrictions, quarantines and other restrictions became prevalent in the United States, this had a negative impact on the Company’s recurring revenue model and its financial position and cash flow. The virus has disrupted the supply chain from China and other countries and the Company depends upon its supply chain to provide a steady source of components to manufacture and repair our devices.

To mitigate the impact of COVID-19 the Company has taken a variety of measures to ensure the availability and functioning of its critical infrastructure by implementing business continuity plans, and to promote the safety and security of its employees while complying with various government mandates, including work-from-home arrangements and social-distancing initiatives to reduce the transmission of COVID-19, such as providing face masks for employees at facilities significantly impacted and requiring on-site body temperature monitoring before entering facilities. In addition, the Company created and executed programs utilizing its direct to consumer advertising and call center to contact patients and partner clinics to restart the Company’s partners’ businesses. To conserve its cash in order to mitigate the on-going impact of the COVID-19 pandemic, in the second quarter, the Company furloughed employees who returned to work after the Company received proceeds from the PPP Loan. The Company also reduced discretionary spending, reduced all inventory purchases and delayed payments to vendors. Delayed payments to vendors were approximately $678 as of December 31, 2020. See Note 2, Liquidity for discussion on Company liquidity.

Basis of Presentation:

Accounting Principles

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary in India. All significant intercompany balances and transactions have been eliminated in consolidation. In 2020 and 2019, there are no operations in the subsidiary in India.

Reclassification

Certain reclassifications from the prior year presentation have been made to conform to the current year presentation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. The more significant estimates include (1) revenue recognition, in regard to deferred revenues and the contract term and valuation allowances of accounts receivable, (2) the inputs used in the impairment analyses of goodwill, (3) the estimated useful lives of intangible assets and property and equipment, (4) the inputs used in determining the fair value of equity-based awards, (5) the valuation allowance related to deferred tax assets (6) the fair value of financial instruments, including derivative instruments and warrants, (7) the inventory reserves, (8) state sales and use tax accruals and (9) warranty claims.

Revenue Recognition

In the Dermatology Recurring Procedures Segment the Company has two types of arrangements for its phototherapy treatment equipment as follows: (i) the Company places its lasers in a physician’s office at no charge to the physician, and generally charges the physician a fee for an agreed upon number of treatments; or (ii) the Company places its lasers in a physician’s office and charges the physician a fixed fee for a specified period of time not to exceed an agreed upon number of treatments; if that number is exceeded additional fees will have to be paid.

For the purposes of U.S. GAAP only, these two types of arrangements are treated under the guidance of ASC 842, Leases. While these arrangements are not contractually operating leases, since the Company sells the physician access codes in order to operate the treatment equipment, these arrangements are similar to operating leases for accounting purposes since the Company provides the customers limited rights to use the treatment equipment and the treatment equipment resides in the physician’s office and the Company may exercise the right to remove the equipment upon notice, under certain circumstances, while the physician controls the utility and output of such equipment during the term of the arrangement as it pertains to the use of access codes to treat the patients. For the lasers placed-in service- under these arrangements, the terms of the domestic arrangements are generally 36 months with automatic one-year renewals and include a termination clause that can be affected at any time by either party with 30 to 60 day notice. Amounts paid are generally non-refundable. For the first type of arrangement, sales of access codes are considered variable treatment code payments and are recognized as revenue over the estimated usage period of the agreed upon number of treatments. For the second type of arrangement, customers purchase access codes and revenue is recognized ratably on a straight-line basis as the lasers are being used over the term period specified in the agreement. Variable treatment code payments that will be paid only if the customer exceeds the agreed upon number of treatments are recognized only when such treatments are being exceeded and used. Internationally, through its Korean, Japanese and, in 2021, Chinese distributors, the Company generally sells access codes for a fixed amount on a monthly basis to end user customers and the terms are generally 48 months, with termination in the event of the customers’ failure to remit payments timely, and include a potential buy-out at the end of the term of the contract. Currently, this is the only foreign recurring revenue. Pre-paid amounts are recorded in deferred revenue and recognized as revenue over the lease term in the patterns described above. Under both methods, pricing is fixed with the customer.

With respect to lease and non-lease components, the Company adopted the practical expedient to account for the arrangement as a single lease component.

In the Dermatology Procedures Equipment segment the Company sells its products internationally through distributors and domestically, directly to a physician. For the product sales, the Company recognizes revenues when control of the promised products is transferred to either the Company’s distributors or end-user customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products (the transaction price). Control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment and legal title must have passed to the customer. The Company ships most of its products FOB shipping point, and as such, the Company primarily transfers control and records revenue upon shipment. From time to time the Company will grant certain customers, for example governmental customers, FOB destination terms, and the transfer of control for revenue recognition occurs upon receipt. The Company has elected to recognize the cost of freight and shipping activities as fulfillment costs. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenues.

Remaining performance obligations related to ASC 606 represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year, which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include the potential obligation to perform under extended warranties but excludes any equipment accounted for as leases. As of December 31, 2020, and 2019, the aggregate amount of the transaction price allocated to remaining performance obligations was $115 and $324, respectively, and the Company expects to recognize $108 and $209, respectively, of the remaining performance obligations within one year and the remainder over one to three years. Contract assets primarily relate to the Company’s rights to consideration for work completed in relation to its services performed but not billed at the reporting date. The contract assets are transferred to receivables when the rights become unconditional. Currently, the Company does not have any contract assets which have not transferred to a receivable. Contract liabilities primarily relate to extended warranties where the Company has received payments, but has not yet satisfied the related performance obligations.

The allocations of the transaction price are based on the price of stand-alone warranty contracts sold in the ordinary course of business. The advance consideration received from customers for the warranty services is a contract liability that is recognized ratably over the warranty period. As of December 31, 2020, and 2019, the $108 and $209 of short-term contract liabilities, respectively, is presented as deferred revenues and the $7 and $115 of long-term contract liabilities, respectively, is presented within Other Liabilities on the Consolidated Balance Sheet, respectively. For the year ended December 31, 2020, and 2019, the Company recognized $209 and $155, respectively, as revenue from amounts classified as contract liabilities (i.e. deferred revenues) as of December 31, 2019, and 2018.

With respect to contract acquisition costs, the Company applied the practical expedient and expenses these costs immediately.

The Company records co-pay reimbursements made to patients receiving laser treatments as a reduction of revenue. For the years ended December 31, 2020, and 2019, the Company recorded such reimbursements in the amounts of $485 and $779, respectively.

Cash and Cash Equivalents and Restricted Cash

Cash and cash equivalents consisted of cash and money market accounts at December 31, 2020, and 2019. The Company invests its cash in highly liquid short-term investments and credit card transactions with settlement terms of less than five days. The Company considers short-term investments that are purchased with an original maturity of three months or less to be cash equivalents. Proceeds due from credit card transactions were $10 and $21 as of December 31, 2020, and 2019, respectively. In connection with the Company’s note payable, the Company pledged the proceeds of a time-deposit account in the amount of the loan and interest and recorded the cash security as restricted cash.

Accounts Receivable, net

The majority of the Company’s accounts receivable are due from physicians, distributors (international) and other entities in the medical field. Accounts receivable are most often due within 30 to 90 days and are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company and available information about their credit risk, and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are considered uncollectible, and payments subsequently received on such receivables are credited to the bad debt expense. The Company does not recognize interest accruing on accounts receivable past due. The allowance for doubtful accounts was $274 and $184 at December 31, 2020, and 2019, respectively.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined based on purchased cost for raw materials and all production cost related to the laser manufacturing process (labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods is classified as inventory. For the Company’s products, cost is determined on the first-in, first-out method. Work-in-process is immaterial, given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.

The Company’s equipment for the treatment of skin disorders (e.g. the XTRAC) will either (i) be placed in a physician’s office and remain the property of the Company (at which date such equipment is transferred to property and equipment) or (ii) be sold to distributors or physicians directly. The cost to build a laser, whether for sale or for placement, is accumulated in inventory.

Reserves for slow moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trends. As of December 31, 2020, and 2019, reserves on inventory were $225 at each date, respectively.

Property, Equipment and Depreciation

Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Excimer lasers-in-service are depreciated on a straight-line basis over the estimated useful life of five years. For other property and equipment, depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, primarily three to seven years for computer hardware and software, furniture and fixtures, and machinery and equipment. Leasehold improvements are amortized over the lesser of the useful lives or lease terms. Expenditures for major renewals and betterments to property and equipment are capitalized, while expenditures for maintenance and repairs are charged as an expense as incurred. Upon retirement or disposition, the applicable property amounts are deducted from the accounts and any gain or loss is recorded in the consolidated statements of operations. Useful lives are determined based upon an estimate of either physical or economic obsolescence or both.

Intangible Assets

Intangible assets consist of core technology, product technology, customer relationships, trademarks and distribution rights. Intangible assets are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from three to ten years.

Accounting for the Impairment of Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in a business combination. The Company evaluates the carrying value of goodwill annually in December of each year in connection with the annual budgeting and forecast process and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, the Company may first perform an assessment qualitatively whether it is more likely than not that a reporting unit’s carrying amount exceeds its fair value. Under Accounting Standards Update (“ASU”) 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” Step 2 from the goodwill impairment test has been eliminated and goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value. As the Company has not identified a goodwill impairment loss, currently this guidance does not have an impact on the Company’s financial statements but could have an effect in the event of a goodwill impairment. The Company bypassed the qualitative assessment and did a quantitative assessment by comparing the fair value of a reporting unit with its carrying amount. No goodwill impairment was identified in the years ended December 31, 2020, and 2019.

Impairment of Long-Lived Assets and Intangibles

Long-lived assets, such as property and equipment, right-of-use assets and definite-lived intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to the undiscounted cash flows attributable to the asset group. If the carrying amount of an asset group exceeds its undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds its fair value.

Functional Currency

The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (“$” or “dollars”). Substantially all of the Company’s revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar.

For foreign currency transactions, the exchange rates applicable to the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates are recorded in financing income or expenses.

Fair Value Measurements

The Company measures and discloses fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.

•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.

•

Level 3 – pricing inputs are unobservable for the asset or liability and only used when there is little, if any, market activity for the asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors.

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

The fair value of cash and cash equivalents and restricted cash are based on their respective demand value, which are equal to the carrying value. The fair value of derivative warrant liability was estimated using option pricing models that was based on the fair value of the Company’s common stock as well as assumptions for volatility, remaining expected life, and the risk-free interest rate. The derivative warrant liability was the only recurring Level 3 fair value measure which expired in 2019. The carrying value of all other short-term monetary assets and liabilities is estimated to be approximate to their fair value due to the short-term nature of these instruments. At December 31, 2019, the Company repaid its long-term debt and now has a short-term note payable that was renewed through December 30, 2021. The carrying value of this note and the Company’s long tem debt are estimated to approximate fair value.

The Company’s warrant liabilities were recorded at their fair value using binomial and Black-Scholes methods and continued- to be recorded at their respective fair value at each subsequent balance sheet date until such terms expired in February and April, 2019. (See Note 12, Warrants, for additional discussion).

Accrued Warranty Costs

The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in Other Accrued Liabilities and Other liabilities on the consolidated balance sheets. The activity in the warranty accrual during the years ended December 31, 2020, and 2019, is summarized as follows:

	December 31,
	2020			2019

Accrual at beginning of year	$	232		$	238
Additions charged to warranty expense		67			222
Expiring warranties/claims satisfied		(186	)		(228	)
Total		113			232
Less: current portion		(87	)		(170	)
Total long-term accrued warranty costs	$	26		$	62

Product Development Costs

Costs of research, new product development and product redesign are charged to expenses as incurred in engineering and product development in the accompanying consolidated statements of operations. The Company incurred $1,274 and $1,002 in engineering and product development costs for the years ended December 31, 2020, and 2019, respectively.

Advertising Costs

Advertising costs are charged to expenses as incurred. Advertising expenses amounted to approximately $697 and $1,936 for the years ended December 31, 2020, and 2019, respectively.

Income Taxes

The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities, as well as on net operating loss carryforwards, and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is not more likely than not that all or some portion of the deferred tax asset will be realized.

The Company accounts for uncertain tax positions in accordance with an amendment to ASC Topic 740-10, Income Taxes (Accounting for Uncertainty in Income Taxes), which clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position can be recognized in the financial statements only if the position is “more-likely-than-not” to be sustained were it to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the “more-likely-than-not” threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded. The Company has no uncertain tax positions.

Concentration of Credit Risks

Financial instruments which subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and accounts receivable. The Company deposits cash and cash equivalents and restricted cash in major financial institutions in the US which, at times exceeds Federal Deposit Insurance Corporation and Securities Investor Protection Corporation limits. The Company performs periodic evaluations of the relative credit standing of these institutions. The Company is of the opinion that the credit risk in respect of these balances is immaterial. In addition, the Company performs periodic credit evaluation and establishes an allowance for doubtful accounts based upon factors surrounding the credit risk of customers. (See also Accounts receivable above).

With the exception of the Company’s international distributor, as described in Note 18, Significant Customer Concentrations, the balance of the Company’s trade receivables does not represent a substantial concentration of credit risk. Most of the Company’s sales are generated in North America, to a large number of customers.

Management periodically evaluates the collectability of the trade receivables to determine the amounts that are doubtful of collection and determine a proper allowance for doubtful accounts.

Earnings Per Share

The Company calculates loss per common share and Preferred Series C share in accordance with ASC 260, Earnings per Share. Under ASC 260, basic loss per common share and Preferred Series C share is calculated by dividing net loss attributable to common shares and Preferred Series C shares by the weighted-average number of common shares and Preferred Series C shares outstanding during the reporting period and excludes dilution for potentially dilutive securities. Diluted loss per common share and Preferred Series C share gives effect to dilutive options, warrants and other potential common shares outstanding during the period.

Shares of Company’s Series C Convertible Preferred Stock are subordinate to all other securities at the same subordination level as common stock and they participate in all dividends and distributions declared or paid with respect to common stock of the Company, on an as-converted basis. Therefore, the Series C Convertible Preferred Stock meet the definition of common stock under ASC 260. Earnings per share is presented for each class of security meeting the definition of common stock. The loss is allocated to each class of security meeting the definition of common stock based on their contractual terms.

The following table presents the calculation of basic and diluted loss per share by each class of security for the years ended December 31, 2020, and 2019:

	Year ended						Year ended
	December 31, 2020						December 31, 2019
	Common Stock			Series C Convertible Preferred Stock			Common Stock			Series C Convertible Preferred Stock

Loss attributable to each class	$	(4,394	)	$	(18	)	$	(3,597	)	$	(193	)

Weighted average number of shares outstanding during the period		33,609,922			368			31,978,665			4,577

Basic and Diluted loss per share	$	(0.13	)	$	(48.59	)	$	(0.11	)	$	(42.24	)

The Company considered Series C Preferred Stock and 403,090 warrants issued on October 31, 2013 and February 14, 2014, to be participating securities in the presentation of earnings per share. However, the warrants are excluded from the calculation of earnings per share in periods of losses as the warrant holders do not have an obligation to fund such losses. The above referenced warrants expired on April 30, 2019 and February 14, 2019.

For the years ended December 31, 2020, and 2019, diluted loss per common share and Series C Convertible Preferred Stock share is equal to the basic loss per common share and Series C Convertible Preferred Stock share, respectively, since all potentially dilutive securities are anti-dilutive. All Series C Convertible Preferred Stock was converted to common stock during the year ended December 31, 2020.

The following common stock equivalents outstanding during the years ended December 31, 2020, and 2019, have been excluded from the loss per share calculation as their inclusion would have been anti-dilutive:

	Year Ended December 31,
		2020	2019
Common stock purchase warrants		434,791	1,517,528
Restricted stock units		131,247	128,417
Common stock options		4,957,288	4,235,451
Total		5,523,326	5,881,396

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC Topic 718, Compensation – Stock Compensation. Under the fair value recognition provision of this statement, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense over the requisite service period of the stock award on a straight-line basis. Forfeitures are recognized when they occur. Performance-based awards are recognized only when it is probable that the vesting conditions will be met. There were no performance awards granted in 2020 or 2019.

Accounting Pronouncements Recently Adopted

In February 2016 the FASB issued ASU 2016-02, “Leases” (Topic 842) (“ASU 2016-02”), which will require lessees to recognize assets and liabilities for leases with lease terms of more than 12 months. Consistent with current U.S. GAAP, the recognition, measurement and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. However, unlike current U.S. GAAP, which requires only capital leases to be recognized on the balance sheet, the new guidance requires both types of leases to be recognized on the balance sheet. The ASU is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. In August 2018 the FASB issued ASU No. 2018-11, “Leases (Topic 842: Targeted Improvements”) which permits adoption of the guidance in ASU 2016-02 using either a modified retrospective transition, requiring application at the beginning of the earliest comparative period presented or a transition method whereby companies could continue to apply existing lease guidance during the comparative periods and apply the new lease requirements through a cumulative-effect adjustment in the period of adoption rather than in the earliest period presented without adjusting historical financial statements.

The Company used the modified retrospective transition approach to ASU No. 2018-11 and applied the new lease requirements through a cumulative-effect adjustment in the period of adoption. The new standard provides a number of optional practical expedients in transition. We elected the package of practical expedients, which permits us not to reassess, under the new standard, our prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us. This accounting standard did not have a material impact on our debt covenants. The Company has completed an evaluation of ASU 2016-02, including a review of our leases and other contracts for potential embedded leasing arrangements and has recognized approximately $848 in right-of-use assets and lease liabilities in the balance sheet as of January 1, 2019. There was no impact on the Company’s revenue recognition under ASC 842.

In June 2018 the FASB issued ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,” with the objective of simplifying several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The provisions of this update are effective for fiscal years beginning after December 15, 2018, including interim periods within that year. The adoption of ASU No. 2018-07 on January 1, 2019, did not have a material effect on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The adoption of ASU No. 2018-13 did not have a material effect on the Company’s consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance eliminated Step 2 from the goodwill impairment test which was required in computing the implied fair value of goodwill. Instead, under the new amendments, an entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. If applicable, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The amendments in this guidance are effective for public business entities for annual and interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019 with early adoption permitted after January 1, 2017. The adoption of ASU No. 2017-04 on January 1, 2020, did not have a material effect on the Company’s consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Statements. This pronouncement provides temporary optional expedients and exceptions for applying U.S. GAAP principles to contract modifications and hedging relationships to ease the financial reporting burdens of the expected market transition from LIBOR and other interbank offered rates to alternative reference rates. The guidance is effective upon issuance in March 2020, and will apply through December 31, 2022. We continue to evaluate the temporary expedients and options available under this guidance, and the effects of these pronouncements and as the Company does not have any hedging activities does not believe this will have a material effect on the Company’s consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40); Accounting for Convertible Instruments and Contracts in an Entity’s own Equity. The pronouncement simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, the ASU “simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP.” In addition, the ASU “removes certain settlement conditions that are required for equity contracts to qualify for it” and “simplifies the diluted earnings per share (EPS) calculations in certain areas. ”The guidance is effective beginning after December 15, 2021 and early adoption is permitted. The Company does not currently engage in contracts covered by this guidance and does not believe it will have a material effect on the Company’s consolidated financial statements, but could in the future.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December15, 2020, with early adoption permitted.

The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.

Liquidity	12 Months Ended
Liquidity	Dec. 31, 2020
Liquidity [Abstract]
Liquidity	Note 2 Liquidity The Company has been negatively impacted by the COVID-19 pandemic, and has historically experienced recurring losses and has been dependent on raising capital from the sale of securities in order to continue to operate and meet the Company’s obligations in the ordinary course of business. Since the equity financing in May 2018 and a change in management, and prior to COVID, the Company had improved revenues, gross profit, generated positive cash flow from operations, refinanced its debt at a lower interest rate and received cash proceeds from the Paycheck Protection Program loan (the “PPP loan”) and the EIDL loan (defined in Note 9 below). Management believes that the Company’s cash and cash equivalents, combined with the anticipated revenues from the sale or use of the Company’s products and the proceeds from the PPP loan and the EIDL loan, will be sufficient to satisfy our working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with our existing operations through the next 12 months following the date of the issuance of these consolidated financial statements. However, the negative impact of the COVID-19 outbreak on the financial markets could interfere with our ability to access financing and to access it on favorable terms, if at all.

Revenue

12 Months Ended

Dec. 31, 2020

Revenue [Abstract]

Revenue

Note 3

Revenue:

The following table presents the Company’s revenue disaggregated by geographical region for the years ended December 31, 2020, and 2019. Domestic refers to revenue from customers based in the United States, and foreign recurring revenue is derived from the Company’s distributor for physicians based in Korea and dermatology procedures equipment revenue is derived from sales to the Company’s international master distributors for physicians based in primarily Asia.

	Year Ended December 31, 2020
	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	16,848	$	956	$	17,804
Foreign		561		4,725		5,286
Total	$	17,409	$	5,681	$	23,090

	Year Ended December 31, 2019
	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	23,645	$	1,243	$	24,888
Foreign		68		6,630		6,698
Total	$	23,713	$	7,837	$	31,586

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international recurring revenue customers as of December 31,

2021	$	948
2022		954
2023		867
2024		440
2025		35
Total	$	3,244

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Inventories

12 Months Ended

Dec. 31, 2020

Inventories [Abstract]

Inventories

Note 4

Inventories:

	December 31, 2020		December 31, 2019

Raw materials and work in process	$	2,949	$	2,651
Finished goods		495		376
	$	3,444	$	3,027

Work-in-process is immaterial, given the Company’s typically short manufacturing cycle, and therefore is included in with raw materials.

Property and Equipment, net

12 Months Ended

Dec. 31, 2020

Property and Equipment, net [Abstract]

Property and Equipment, net

Note 5

Property and Equipment, net:

	December 31, 2020			December 31, 2019

Lasers placed-in-service	$	22,942		$	20,925
Equipment, computer hardware and software		146			146
Furniture and fixtures		243			234
Leasehold improvements		43			26
		23,374			21,331
Accumulated depreciation and amortization		(17,845	)		(15,962	)
Property and equipment, net	$	5,529		$	5,369

Depreciation and related amortization expense was $1,975 and $2,693 for the years ended December 31, 2020, and 2019, respectively.

Intangible Assets, net

12 Months Ended

Dec. 31, 2020

Intangible Assets, net [Abstract]

Intangible Assets, net

Note 6

Intangible Assets, net:

Set forth below is a detailed listing of definite-lived intangible assets as of:

	December 31,
	2020										2019
	Balance			Accumulated Amortization				Intangible assets, net			Intangible assets, net

Core technology		$	5,700		$	(3,135	)		$	2,565	$	3,135
Product technology			2,000			(2,000	)			-		200
Customer relationships			6,900			(3,795	)			3,105		3,795
Tradenames			1,500			(825	)			675		825
		$	16,100		$	(9,755	)		$	6,345	$	7,955

Related amortization expense was $1,610 and $1,810 for the years ended December 31, 2020, and 2019, respectively. Total accumulated amortization at December 31, 2019 was $8,145. Intangible assets consist of core technology, product technology, customer relationships, trademark and distribution rights. Intangible assets are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from three to ten years.

Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:

2021	$	1,410
2022		1,410
2023		1,410
2024		1,410
2025		705
Total	$	6,345

Goodwill

12 Months Ended

Dec. 31, 2020

Goodwill [Abstract]

Goodwill

Note 7

Goodwill:

Goodwill reflects the amount of the acquisition price in excess of the fair values assigned to identifiable tangible and intangible assets and assumed liabilities. Goodwill is not amortized, but is reviewed annually for impairment. Goodwill was recorded on the acquisition of the XTRAC and VTRAC businesses on June 22, 2015, as the purchase price exceeded the fair value of the identifiable net assets of the business. The balance of goodwill at December 31, 2020, and 2019 consisted of the following:

Dermatology Recurring Procedures segment	$	7,958
Dermatology Procedures Equipment segment		845
Total	$	8,803

The Company has incurred no impairment of goodwill as of December 31, 2020 and 2019.

Other Accrued Liabilities

12 Months Ended

Dec. 31, 2020

Other Accrued Liabilities [Abstract]

Other Accrued Liabilities

Note 8

Other Accrued Liabilities:

	December 31, 2020		December 31, 2019

Accrued warranty, current, see Note 1	$	87	$	170
Accrued compensation, including commissions and vacation		891		1,193
Accrued state sales use and other taxes		3,105		3,193
Accrued professional fees and other accrued liabilities		607		578
Total other accrued liabilities	$	4,690	$	5,134

In the ordinary course of business, the Company is, from time to time, subject to audits performed by state taxing authorities. These actions and proceedings are generally based on the position that the arrangements entered into by the Company are subject to sales and use tax rather than exempt from tax under applicable law. The Company uses estimates when accruing its sales and use tax liability. All of the Company’s tax positions are subject to audit. One state has assessed the Company, in two assessments, an aggregate amount of $1,484 for the period from March 2014 through February 2020 including penalties and interest. The Company has declined an informal offer to settle at a substantially lower amount and the Company appealed in that jurisdiction’s administrative process of appeal.

In January 2021, the Company received notification that the administrative judge from the respective state had issued an opinion finding in favor of the Company that the sale of XTRAC treatment codes were not taxable as sales tax with respect to the first assessment. The jurisdiction has 30 days plus extensions to file an appeal and on March 25^th the Company received an advisory from the jurisdiction that it would file an appeal.

A second jurisdiction has made an assessment of $720 from June 2015 through March 2018 plus interest of $171 through April 2020. The Company is also in that jurisdiction’s administrative process of appeal and the timing of the process has been impacted by the COVID-19 pandemic. If there is a determination that the true object of the Company’s recurring revenue model is not exempt from sales taxes and is not a prescription medicine or the Company does not have other defenses where the Company does not prevail, the Company may be subject to sales taxes in those particular states for previous years and in the future, plus potential interest and penalties for failure to pay such taxes.

The Company believes its state sales and use tax accruals have properly recognized such that if the Company’s arrangements with customers are deemed more likely than not that the Company would not be exempt from sales tax in a particular state are the basis for measurement of the state sales and use tax is calculated in accordance with ASC 405, Liabilities as a transaction tax. If and when the Company is successful in defending itself or in settling the sales tax obligation for a lesser amount, the reversal of this liability is to be recorded in the period the settlement is reached. However, the precise scope, timing and time period at issue, as well as the final outcome of any audit and actual settlement remains uncertain.

The Company records state sales tax collected and remitted for its customers on equipment sales on a net basis, excluded from revenue. The Company’s sales tax expense that is not presently being collected and remitted for the recurring revenue business are recorded in general and administrative expenses on the consolidated statements of operations.

Note Payable	12 Months Ended
Note Payable	Dec. 31, 2020
Note Payable [Abstract]
Note Payable	Note 9 Note Payable On December 30, 2019, the Company closed on a $7,275 loan with a commercial bank pursuant to a one-year Fixed Rate – Term Promissory Note (the “Note”), which was renewed effective December 30, 2020 at an interest rate of 1.40% and a rate of 0.40% on the time deposit. For the year ended December 31, 2019 the Note had an interest rate of 2.79% and a rate of 1.79% on the time deposit. The Company’s obligations under the Note are secured by an Assignment and Pledge of Time Deposit (the “Agreement”), under which the Company has pledged to the commercial bank the proceeds of a time deposit account in the amount of the loan and recorded the time deposit and interest as restricted cash on the balance sheet. The principal is due on December 30, 2021 with no penalties for prepayments. In 2019, the Company fully repaid (including payment of termination and exit fees) its then existing long-term debt credit facility with Midcap Financial Trust (“MidCap”). The transaction was accounted for as a debt extinguishment. See Note 10 Long-term Debt for further discussion on the extinguishment.

Long-term Debt

12 Months Ended

Dec. 31, 2020

Long-term Debt [Abstract]

Long-term Debt

Note 10

Long-term Debt:

Term-Note Credit Facility

On December 30, 2015, the Company entered into a $12,000 credit facility pursuant to a Credit and Security Agreement (the “Credit Agreement”) and related financing documents with MidCap and the lenders listed therein. Under the Credit Agreement, the credit facility could be drawn down in two tranches, the first of which was drawn for $10,500 on December 30, 2015. The second tranche was drawn for $1,500 on January 29, 2016. The maturity date of the credit facility was December 1, 2020. The Company’s obligations under the credit facility were secured by a first priority lien on all the Company’s assets. This credit facility had an interest rate of one-month LIBOR plus 8.25% and included both financial and non-financial covenants, including a minimum net revenue covenant. On November 10, 2017, the minimum net revenue covenant was amended prospectively and there was an increase in the exit fee. Additionally, on November 10, 2017, the Company entered into an amendment to modify the principal payments, including a period of six months where there were no principal payments due.

On March 26, 2018, the Company entered into a Third Amendment to the Credit Agreement with MidCap. For the period beginning on the closing date of the loan and ending on January 31, 2018, the gross revenue in accordance with U.S. GAAP for the twelve-month period ending on the last day of the most recently completed calendar month was amended to be less than the minimum amount on the Covenant Schedule, as defined in the Credit Agreement. This amendment waived the event of default related to the revenue covenant for the period ending February 2018. This amendment also amended the monthly net revenue covenant.

On May 29, 2018, the Company entered into a Fourth Amendment to Credit Agreement (the “Amendment”), pursuant to which the Company repaid $3,000 in principal of then existing $10,571 credit facility. The terms of the credit facility were amended to impose less restrictive covenants and lower prepayment fees for the Company and extended the maturity date to May 2022. The Amendment modified the principal payments including a period of 18 months where there were no principal payments due. Principal payments beginning December 2019 were $252 plus interest per month. The interest rate on the credit facility was one-month LIBOR plus 7.25%. On April 30, July 15, August 26, and October 15, 2019 the Company received waivers from MidCap, as administrative agent for the lenders who were party to the Credit Agreement, wherein the lenders waived the Company’s compliance with the obligation to deliver audited financial statements within 120 days of year-end, pursuant to the Credit Agreement. The waivers were effective through November 7, 2019. The Company delivered the audited financial statements on or about October 29, 2019 to cure the event of default.

These amendments had been accounted for as debt modifications, as the present value of the cash flows changed by less than 10%.

All borrowings under the Credit Agreement were fully repaid in connection with the proceeds from a Fixed Rate-Promissory Note on December 30, 2019. The Company accounted for the repayment as an extinguishment of debt and recorded a loss of $414 in the consolidated statements operations for the year ended December 31, 2019.

Paycheck Protection Program Loan

On April 22, 2020, the Company closed a loan of $2,028 (the “PPP loan”) from a commercial bank, pursuant to the Paycheck Protection Program (“PPP”) administered by the Small Business Administration (the “SBA”) pursuant to the CARES Act. The PPP loan matures on May 1, 2022 and bears an interest rate of 1% per annum. Payments of principal and interest of any unforgiven balance was scheduled to commence December 1, 2020, but is deferred until the SBA approves of the forgiveness amount. Under the Paycheck Protection Program Flexibility Act of 2020 (the “PPP Flexibility Act”), (i) the first payment date for the PPP loan will be the earlier of (a) 10 months after the end of the “covered period” (as determined under the PPP) or (b) the date the bank receives a remittance of the forgiven amount from the SBA, and (ii) the PPP loan’s maturity is extended to five years (from 2 years).

All or a portion of the PPP loan may be forgiven by the lender upon application by the Company beginning 60 days after loan approval and upon documentation of expenditures in accordance with the requirements set forth by the SBA pursuant to the CARES Act. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities at either; the Company’s election, the eight-week period or twenty-four week period beginning on the date of disbursement of proceeds from the PPP loan. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100, prorated annually. Not more than 40% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced, under certain circumstances, if full-time headcount declines or if salaries and wages for employees with salaries of $100 or less annually are reduced. In the event the PPP loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. In December 2020, the Company has submitted for forgiveness to the SBA, and subject to the SBA’s approval, of 100% of the loan proceeds. The balance of the loan at December 31, 2020 was $2,028.

Economic Injury Disaster Loan

On May 22, 2020, the Company executed the standard loan documents required for securing a loan (the “EIDL Loan”) from the SBA under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business. The principal amount of the EIDL Loan is up to $500, with proceeds to be used for working capital purposes and is collateralized by all the Company’s assets. On June 12, 2020, the Company received these funds from the SBA. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due monthly beginning March 26, 2021 (twelve months from the date of the promissory note) in the amount of $2. The balance of principal and interest is payable over the next thirty years from the date of the promissory note. There are no penalties for prepayment. Based upon guidance issued by the SBA on June 19, 2020, the EIDL Loan is not required to be refinanced by the PPP loan. The balance of the loan at December 31, 2020 was $500.

The following summarizes the Company’s long term debt:

Term notes	$	2,528
Less: current portion		(1,478	)
Total long-term debt	$	1,050

The following table summarizes the future payments that the Company is obligated to make for long-term debt for the future period as to the stated terms of the loans:

2021	$	1,478
2022		568
2023		10
2024		10
2025		10
Thereafter		452
Total	$	2,528

Commitments and Contingencies

12 Months Ended

Dec. 31, 2020

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Note 11

Commitments and Contingencies:

Leases

The Company recognizes right-of-use assets (“ROU Assets”) and operating lease liabilities (“Lease Liabilities”) when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company adopted the short-term accounting election for leases with a duration of less than one year. The Company leases its facilities and certain IT and office equipment under non-cancellable operating leases.

All of the Company’s leasing arrangements are classified as operating leases with remaining lease terms ranging from 1 to 4 years, and one facility lease has a renewal option for two years. Renewal options have been excluded from the determination of the lease term as they are not reasonably certain of exercise. On May 1, 2019, the Company entered into an addendum with FR National Life, LLC for the Carlsbad facility for five years which began on October 1, 2019.

Operating lease costs were $448 for each of the years ended December 31, 2020 and 2019. Cash paid for amounts included in the measurement of operating lease liabilities was $436 and $371 for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, and 2019, the incremental borrowing rate was 9.76% and the weighted average remaining lease term was 3.1 and 4.1 years, respectively. The following table summarizes the Company’s operating lease maturities as of December 31, 2020:

For the year ending December 31,
2021	$	456
2022		371
2023		242
2024		186
Total remaining lease payments		1,255
Less: imputed interest		(176	)
Total lease liabilities	$	1,079

With respect to lease and non-lease components, the Company adopted the practical expedient to account for the lessee arrangement as a single lease component.

Contingent Shares

In the event of certain contingencies, the investors in the an equity financing in May 2018 may receive additional shares issued pursuant to the Retained Risk Provisions as defined in the Stock Purchase Agreements. There are additional contingencies included in the SPAs that the Company has determined are not probable or estimable and/or contractually obligated in order to issue shares at this time.

For contingencies related to sales and use taxes, see Note 8.

Litigation

In the ordinary course of business, the Company is routinely a defendant in or party to pending and threatened legal actions and proceedings, including actions brought on behalf of various classes of claimants. These actions and proceedings are generally based on alleged violations of employment, contract and other laws. In some of these actions and proceedings, claims for substantial monetary damages are asserted against the Company. In the ordinary course of business, the Company is also subject to regulatory and governmental examinations, information gathering requests, inquiries, investigations, and threatened legal actions and proceedings. In connection with formal and informal inquiries by federal, state, local and foreign agencies, the Company receives numerous requests, subpoenas and orders for documents, testimony and information in connection with various aspects of its activities.

Warrants	12 Months Ended
Warrants	Dec. 31, 2020
Warrants [Abstract]
Warrants	Note 12 Warrants: The Company accounts for warrants that require net cash settlement upon change of control of the Company as liabilities instead of equity. There were 403,090 of such warrants with an exercise price of $3.75 per share which expired on February 5, 2019 and April 30, 2019.

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2020
Stockholders' Equity [Abstract]
Stockholders' Equity	Note 13 Stockholders’ Equity: Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors. Other than the limitations on conversions to keep each such holder’s beneficial ownership below 9.99%, the terms of the Series C Convertible Preferred Stock generally bestow the same rights to each holder as such holder would receive if they were common stock shareholders and are not redeemable by the holders, except that the Series C Convertible Preferred Stock shares do not have voting rights. The Series C Convertible Preferred Stock have the same level of subordination as common stock. Each share of Series C Convertible Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at a conversion price equal to $2.69 for a total of approximately 15,049,000 shares of common stock. There were 0 and 2,103 shares of Series C Convertible Preferred Stock issued and outstanding on December 31, 2020, and 2019, respectively. For the years ended December 31, 2020, and 2019, investors converted shares of Series C Preferred Stock into 782,089 and 2,923,791 shares of common stock, respectively. Common Stock and Warrants The Company is authorized to issue 150,000,000 shares of common stock with a par value of $0.001 per share. There were 33,801,045 and 32,932,273 shares of common stock issued and outstanding at December 31, 2020, and 2019, respectively. At December 31, 2020, the Company had 19,812 outstanding common stock warrants with an exercise price of $5.30. These warrants expired on January 29, 2021.

Stock-based compensation

12 Months Ended

Dec. 31, 2020

Stock-based compensation [Abstract]

Stock-based compensation

Note 14

Stock-based compensation:

Stock Options

On October 27, 2016, the Company’s stockholders approved the Company’s adoption of the new 2016 Omnibus Incentive Stock Plan (“2016 Plan”) having 2,058,880 shares available for issuance in respect of awards made thereunder. The Company terminated the 2013 Stock Incentive Plan in October 2016. On May 29, 2018, the Company’s stockholders approved the Company’s amendment to the 2016 Plan to increase the number of the Company’s common stock available for grants under the plan by 3,134,365. As of December 31, 2020, the aggregate number of shares of common stock remaining available for issuance for awards under the 2016 Plan totaled 41,774.

A summary of option transactions for all of the Company’s stock options during the years ended December 31, 2020, and 2019 follows:

	Number of Stock Options			Weighted Average Exercise Price
Outstanding at January 1, 2019		4,342,765		$	2.02
Granted		875,000			2.46
Exercised		(86,250	)		1.74
Expired/forfeited		(223,477	)		6.43
Outstanding at December 31, 2019		4,908,038			1.90
Granted		400,000			1.46
Exercised		(15,000	)		1.29
Expired/forfeited		(150	)		170.00
Outstanding at December 31, 2020		5,292,888		$	1.87
Exercisable at December 31, 2020		3,442,501		$	1.87
Options expected to vest at December 31, 2020		1,850,387		$	1.86

The outstanding options at December 31, 2020, have a range of exercise prices and associated weighted remaining contractual life and weighted average exercise price, as follows:

Options Range of Exercise Prices		Outstanding Number of Shares		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Exercisable Number of Shares		Exercisable Weighted Average Exercise Price
$	1.11 - $2.00		4,185,877		7.59	$	1.47		2,918,323	$	1.43
$	2.01 - $5.00		941,000		8.67		2.52		358,267		2.61
$	5.01 - $181.00		166,011		4.54		8.07		165,911		8.03
Total			5,292,888		7.69	$	1.87		3,442,501	$	1.87

The weighted average remaining contractual life of exercisable options was 7.30 years and 8.03 years at December 31, 2020, and 2019, respectively.

The share price as of December 31, 2020, was $1.50 and the aggregate intrinsic value for options outstanding and exercisable was $611 and $546, respectively. The intrinsic value of the options that were exercised was $3 during the year ended December 31, 2020. The share price for December 31, 2019, was $2.08 and the intrinsic value for options outstanding and exercisable was $2,300 and $1,156, respectively.

Stock awards under the Company’s stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the plans are generally time-based or performance-based options and vesting varies accordingly (see below for specific vesting conditions). There were no performance-based options granted in 2020 or 2019. Options under the plans expire up to a maximum of ten years from the date of grant. The fair value of each option award granted during the period is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

	Years Ended December 31,
	2020	2019
Risk-free interest rate	.53%	1.66%
Volatility	94%	71%
Expected dividend yield	0%	0%
Expected life	6.0 years	6.0 years

The expected life of the options is based on the observed and expected time to full-vesting, forfeiture and exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. Volatility is based on Company historical volatility and comparable companies’ historical stock prices matching the expected term of the award. The risk-free rate is based on rates provided by the U.S. Treasury with a term equal to the expected life of the option. The Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.

For the year ended December 31, 2019, 86,250 of options were exercised in a cashless exercise at a weighted average exercise price of $1.74 which resulted in the issuance of 36,410 of shares of common stock. For the year ended December 31, 2020, 15,000 of options were exercised at a weighted average exercise price of $1.29.

On November 21, 2019, the Company granted options to purchase 300,000 shares of common stock to its Chief Executive Officer, 150,000 shares of common stock to its Chief Financial Officer and 425,000 in additional grants to management at a strike price of $2.46. The options vest over three years and expire ten years from the date of grant. The aggregate fair value of the options granted was $1,361.

On November 13, 2020, the Company granted options to purchase 150,000 shares of common stock to its Chief Financial Officer and 250,000 in additional grants to management at a strike price of $1.46. The options vest over three years and expire ten years from the date of grant. The aggregate fair value of the options granted was $443.

The following table summarizes the Company’s unvested stock option activity:

	Options			Weighted Average Grant Date Fair Value
Unvested balance as of January 1, 2019		3,394,468		$	0.82
Granted		875,000			1.56
Vested		(1,265,956	)		0.78
Forfeited/expired		-			-
Unvested balance as of December 31, 2019		3,003,512		$	1.05
Granted		400,000			1.11
Vested		(1,553,125	)		0.96
Forfeited/expired		-			-
Unvested balance at December 31, 2020		1,850,387		$	1.15

Restricted Stock Units

In connection with the closing of an equity financing in May 2018, there were changes to the board of directors and the Company issued initial grants to new members as well as grants to all members as compensation. In total, the Company granted 140,097 restricted stock units to the board members at a fair value of $2.07. The restricted stock units vest quarterly over twelve months. The aggregate fair value of the restricted stock units granted was $290. Restricted stock units issued to the Chairman were cancelled in January 2019.

On November 21, 2019, the Company granted 77,237 restricted stock units to certain board members at a fair value of $2.46. The restricted stock units vest quarterly over twelve months. The aggregate fair value of the restricted stock units granted was $190.

Stock-based compensation expense, which is included in general and administrative expense, for the years ended December 31, 2020, and 2019, was $1,633 and $1,195, respectively. As of December 31, 2020, there was $1,715 in unrecognized compensation expense, which will be recognized over a weighted average period of 1.05 years.

Restricted stock unit unvested are summarized in the following table:

	Number of restricted stock units			Weighted Average Grant Date Fair Value
Unvested balance at January 1, 2019		70,049		$	2.07
Granted		77,237			2.46
Vested/settled		(60,387	)		2.07
Forfeited/expired		(9,662	)		2.07
Unvested balance at December 31, 2019		77,237		$	2.46
Granted		-			-
Vested/settled		(68,091	)		2.46
Forfeited/expired		(9,146	)		2.46
Unvested balance at December 31, 2020		-		$	-

At December 31, 2020 and 2019, restricted stock units vested but not issued were 88,194 and 91,787, respectively.

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Taxes [Abstract]

Income Taxes

Note 15

Income Taxes:

	Years Ended December 31,
	2020		2019
Current:
Federal	$	-	$	(58	)
State		21		20
		21		(38	)
Deferred:
Federal		129		(86	)
State		125		(25	)
		254		(111	)
Income tax expense (benefit)	$	275	$	(149	)

The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from net operating loss carryforwards and temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is not more likely than not that a tax benefit will be realized.

The CARES ACT, among other things contains numerous income tax provisions. Some of these tax provisions are effective retroactively for the years ending before the date of enactment. The Company analyzed the impact of the CARES ACT and does not foresee a significant impact on its consolidated financial position, results of operations, effective tax rate and cash flows.

The difference between the actual income tax expense (benefit) and that computed by applying the U.S. federal income tax rate to pretax loss from continuing operations is summarized below:

	For the Years Ended December 31,
	2020				2019

Computed expected tax expense (benefit)		$	(869	)		$	(827	)
State tax (benefit)expense, net of federal effect			(272	)			(106	)
Other			221				377
Net increase (decrease) in valuation allowance			1,195				407
Provision for income taxes		$	275			$	(149	)

The computed expected tax benefit was calculated using the U.S. federal income tax rates of 21% for the years ended December 31, 2020, and 2019, respectively.

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2020, and 2019 are as follows:

	December 31,
	2020			2019

Deferred tax assets/(liabilities):
Net operating loss carryforward	$	45,819		$	43,433
Intangible assets		1,450			2,046
Inventory		51			51
Reserves & accrued expenses		896			992
Property & equipment		(178	)		389
Non-cash compensation		808			850
Goodwill		(815	)		(667	)
Right of use asset		(249	)		(331	)
Lease liability		272			350
Total net deferred tax assets		48,054			47,113
Less: valuation allowance		(48,308	)		(47,113	)
Net deferred tax assets/(liabilities)	$	(254	)	$	-

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based on the Company’s historical net losses, management does not believe that it is more-likely-than not that the Company will realize the benefits of these deferred tax assets and, accordingly, nearly a full valuation allowance has been recorded against the deferred tax assets as of December 31, 2020 and 2019. The Company’s valuation allowance against its deferred tax assets increased by $1,195 for the year ended December 31, 2020 and increased by $407 for the year ended December 31, 2019.

At December 31, 2020, and 2019, the Company has federal net operating loss carryforwards of approximately $200,976 to offset future taxable income. Net operating loss carryforwards prior to 2019 begin to expire in 2021 through 2036. The Company has experienced certain ownership changes which, under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, result in annual limitations on the Company’s ability to utilize its net operating losses in the future. The February 2014, July 2014, June 2015 and May 2018 equity raises by the Company will limit the annual use of these net operating loss carryforwards. Although the Company has not performed a Section 382 study, any limitation of its pre-change net operating loss carryforwards that would result in a reduction of its deferred tax asset would also have an equal and offsetting adjustment to the valuation allowance.

FASB ASC 740 “Income Taxes” contains guidance with respect to uncertain tax positions which applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to recognize. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is, greater than 50%, likely of being realized upon ultimate finalization with the taxing authority.

The Company does not have any uncertain income tax positions or accrued penalties and interest. If such matters were to arise, the Company would recognize interest and penalties related to income tax matters in income tax expense. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. The Company’s tax years are still under open status from 2016 to present. All open years may be examined to the extent that net operating loss carryforward are used in future periods.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Business Segments

12 Months Ended

Dec. 31, 2020

Business Segments [Abstract]

Business Segments

Note 16

Business Segments:

The Company organized its business into two operating segments to better align its organization based upon the Company’s management structure, products and services offered, markets served and types of customers, as follows: The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense), net, is also not allocated to the operating segments.

The following tables reflect results of operations from our business segments for the periods indicated below:

Year Ended December 31, 2020

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues	$	17,409		$	5,681		$	23,090
Costs of revenues		5,832			3,124			8,956
Gross profit		11,577			2,557			14,134
Gross profit %		66.5	%		45.0	%		61.2	%

Allocated operating expenses:
Engineering and product development		1,101			173			1,274
Selling and marketing expenses		8,437			601			9,038
Unallocated operating expenses		-			-			7,898
		9,538			774			18,210
Income (loss) from operations		2,039			1,783			(4,076	)
Interest expense, net		-			-			(61	)
Income (loss) before income taxes	$	2,039		$	1,783		$	(4,137	)

Year Ended December 31, 2019

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues	$	23,713		$	7,873		$	31,586
Costs of revenues		7,033			4,283			11,316
Gross profit		16,680			3,590			20,270
Gross profit %		70.3	%		45.6	%		64.2	%

Allocated operating expenses:
Engineering and product development		845			157			1,002
Selling and marketing expenses		11,191			812			12,003
Unallocated operating expenses		-			-			10,275
		12,036			969			23,280
Income (loss) from operations		4,644			2,621			(3,010	)
Interest expense, net		-			-			(515	)
Loss on extinguishment of debt		-			-			(414	)
Income (loss) before income taxes	$	4,644		$	2,621		$	(3,939	)

As of December 31, 2020, and 2019, total assets by reportable segment were as follows:

	December 31,
Assets:	2020		2019
Dermatology Recurring Procedures	$	25,112	$	27,620
Dermatology Procedures Equipment		3,052		3,382
Other unallocated assets		18,614		16,341
Consolidated total	$	46,778	$	47,343

Substantially all long-lived assets were located in domestic markets for both of the years ended December 31, 2020, and 2019.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Related Parties	12 Months Ended
Related Parties	Dec. 31, 2020
Related Parties [Abstract]
Related Parties	Note 17 Related Parties: In connection with the certain litigation, the Company has agreed to indemnify Uri Geiger and Accelmed Growth Partners, L.P. for their out of pocket costs. As of December 31, 2019, the Company has reimbursed Accelmed Growth Partners, L.P. approximately $25.

Significant Customer Concentration	12 Months Ended
Significant Customer Concentration	Dec. 31, 2020
Significant Customer Concentration [Abstract]
Significant Customer Concentration	Note 18 Significant Customer Concentration: For the year ended December 31, 2020, revenue from sales to GlobalMed, the Company’s international master distributor, were $2,679, or 11.6%, of total revenues. At December 31, 2020, the accounts receivable from GlobalMed was less than 10% of total accounts receivable. For the year ended December 31, 2019, revenues from sales to the Company’s international master distributor were $6,133, or 19.4% of total revenues for such year. At December 31, 2019, the accounts receivable balance from GlobalMed was $661, or 15.1%, of total net accounts receivable. No other customer accounted for more than 10% of the Company’s revenues or accounts receivable.

Employee 401(k) Savings Plan	12 Months Ended
Employee 401(k) Savings Plan	Dec. 31, 2020
Employee 401(k) Savings Plan [Abstract]
Employee 401(k) Savings Plan	Note 19 Employee 401(k) Savings Plan: The Company sponsors a 401(k) defined contribution retirement savings plan that covers all eligible employees who have met the minimum age and service requirements. Under the plan, eligible employees may contribute a portion of their annual compensation into the plan up to IRS annual limits. The Company has elected to make matching contributions to the plan based on percentage of the employee’s contribution. For the years ended December 31, 2020, and 2019, the Company’s contributions to the plan were $240 and $248, respectively. On January 1, 2019, the Company elected a safe harbor match to the 401(k) defined contribution plan.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 20 Subsequent Events: On January 29, 2021, 19,812 outstanding common stock warrants expired. On February 24, 2021, the Company and Dr. Dolev Rafaeli entered into an employment separation agreement and release (the “Separation Agreement”), pursuant to which, among other things, Dr. Rafaeli resigned as the Company’s Chief Executive Officer and President and as a member of the Company’s board of directors on February 28, 2021. In connection with Dr. Rafaeli’s separation, upon the expiration of the revocation of a general release delivered by Dr. Rafaeli to the Company, the Company will (i) pay Dr. Rafaeli (a) his base salary, less applicable legal deductions, through May 29, 2021 consistent with normal payroll procedures, (b) a lump sum amount equal to 12 weeks of pay as a payout of his accrued but unused vacation days, (c) reimbursements of his monthly COBRA premium payments for up to 18 months following February 28, 2021, and (d) an amount up to $10,000 to reimburse Dr. Rafaeli for reasonable attorneys’ fees in connection with the negotiation of the Separation Agreement, and (ii) vest all outstanding options held by Dr. Rafaeli (to the extent not then vested) and have them remain exercisable until August 22, 2021. Subject to the foregoing restrictions and the Company’s insider trading policies, Dr. Rafaeli will be permitted to exercise the options as permitted under the Company’s equity incentive plan, including cashless exercises, until August 22, 2021. Certain provisions contained in the employment agreement, dated as of March 30, 2018 (the “Rafaeli Employment Agreement”), between the Company and Dr. Rafaeli survive and continue to apply under the Separation Agreement, including, but not limited to, covenants related to confidentiality, assignment of developments, and covenant not to compete. The Company and Dr. Rafaeli also agreed to mutual non-disparagement and communication restriction provisions and granted customary general releases to each other. Until May 29, 2021, Dr. Rafaeli agreed to cooperate in good faith with the Company in transitioning his duties to one or more persons as determined by the Company’s board of directors. On February 28, 2021, in connection with the separation of the Company’s Chief Executive Officer, the Company accelerated the vesting of options to purchase 800,886 shares of common stock. On March 1, 2021, the Company granted an options to purchase 1,632,590 shares of common stock to its incoming Chief Executive Officer with a strike price of $1.73 vesting over a three year period, with 544,198 options vesting on the first anniversary of the date of the grant and 136,049 vesting every three months thereafter, subject to acceleration of vesting under certain circumstances.

The Company (Policies)

12 Months Ended

Dec. 31, 2020

The Company [Abstract]

Accounting Principles

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Principles of Consolidation

Reclassification

Certain reclassifications from the prior year presentation have been made to conform to the current year presentation.

Use of Estimates

Revenue Recognition

With respect to lease and non-lease components, the Company adopted the practical expedient to account for the arrangement as a single lease component.

With respect to contract acquisition costs, the Company applied the practical expedient and expenses these costs immediately.

Cash and Cash Equivalents and Restricted Cash

Accounts Receivable, net

Inventories

Property, Equipment and Depreciation

Intangible Assets

Accounting for the Impairment of Goodwill

Impairment of Long-Lived Assets and Intangibles

Functional Currency

Fair Value Measurements

•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.

•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.

•

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

Accrued Warranty Costs

	December 31,
	2020			2019

Accrual at beginning of year	$	232		$	238
Additions charged to warranty expense		67			222
Expiring warranties/claims satisfied		(186	)		(228	)
Total		113			232
Less: current portion		(87	)		(170	)
Total long-term accrued warranty costs	$	26		$	62

Product Development Costs

Advertising Costs

Advertising costs are charged to expenses as incurred. Advertising expenses amounted to approximately $697 and $1,936 for the years ended December 31, 2020, and 2019, respectively.

Income Taxes

Concentration of Credit Risks

Management periodically evaluates the collectability of the trade receivables to determine the amounts that are doubtful of collection and determine a proper allowance for doubtful accounts.

Earnings Per Share

The following table presents the calculation of basic and diluted loss per share by each class of security for the years ended December 31, 2020, and 2019:

	Year ended						Year ended
	December 31, 2020						December 31, 2019
	Common Stock			Series C Convertible Preferred Stock			Common Stock			Series C Convertible Preferred Stock

Loss attributable to each class	$	(4,394	)	$	(18	)	$	(3,597	)	$	(193	)

Weighted average number of shares outstanding during the period		33,609,922			368			31,978,665			4,577

Basic and Diluted loss per share	$	(0.13	)	$	(48.59	)	$	(0.11	)	$	(42.24	)

	Year Ended December 31,
		2020	2019
Common stock purchase warrants		434,791	1,517,528
Restricted stock units		131,247	128,417
Common stock options		4,957,288	4,235,451
Total		5,523,326	5,881,396

Stock-Based Compensation

Accounting Pronouncements Recently Adopted and Not Yet Adopted

Accounting Pronouncements Recently Adopted

Recent Accounting Pronouncements Not Yet Adopted

The Company (Tables)

12 Months Ended

Dec. 31, 2020

The Company [Abstract]

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2020, and 2019, is summarized as follows:

	December 31,
	2020			2019

Accrual at beginning of year	$	232		$	238
Additions charged to warranty expense		67			222
Expiring warranties/claims satisfied		(186	)		(228	)
Total		113			232
Less: current portion		(87	)		(170	)
Total long-term accrued warranty costs	$	26		$	62

Calculation of Basic and Diluted Loss Per Share by Class of Security

The following table presents the calculation of basic and diluted loss per share by each class of security for the years ended December 31, 2020, and 2019:

	Year ended						Year ended
	December 31, 2020						December 31, 2019
	Common Stock			Series C Convertible Preferred Stock			Common Stock			Series C Convertible Preferred Stock

Loss attributable to each class	$	(4,394	)	$	(18	)	$	(3,597	)	$	(193	)

Weighted average number of shares outstanding during the period		33,609,922			368			31,978,665			4,577

Basic and Diluted loss per share	$	(0.13	)	$	(48.59	)	$	(0.11	)	$	(42.24	)

Antidilutive Securities Excluded from Computation of Earnings Per Share

	Year Ended December 31,
		2020	2019
Common stock purchase warrants		434,791	1,517,528
Restricted stock units		131,247	128,417
Common stock options		4,957,288	4,235,451
Total		5,523,326	5,881,396

Revenue (Tables)

12 Months Ended

Dec. 31, 2020

Revenue [Abstract]

Disaggregation of Revenue

	Year Ended December 31, 2020
	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	16,848	$	956	$	17,804
Foreign		561		4,725		5,286
Total	$	17,409	$	5,681	$	23,090

	Year Ended December 31, 2019
	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	23,645	$	1,243	$	24,888
Foreign		68		6,630		6,698
Total	$	23,713	$	7,837	$	31,586

Future Undiscounted Fixed Treatment Code Payments from International Recurring Revenue Customers

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international recurring revenue customers as of December 31,

2021	$	948
2022		954
2023		867
2024		440
2025		35
Total	$	3,244

Inventories (Tables)

12 Months Ended

Dec. 31, 2020

Inventories [Abstract]

Inventories

Inventories:

	December 31, 2020		December 31, 2019

Raw materials and work in process	$	2,949	$	2,651
Finished goods		495		376
	$	3,444	$	3,027

Property and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2020

Property and Equipment, net [Abstract]

Property and Equipment, Net

Property and Equipment, net:

	December 31, 2020			December 31, 2019

Lasers placed-in-service	$	22,942		$	20,925
Equipment, computer hardware and software		146			146
Furniture and fixtures		243			234
Leasehold improvements		43			26
		23,374			21,331
Accumulated depreciation and amortization		(17,845	)		(15,962	)
Property and equipment, net	$	5,529		$	5,369

Intangible Assets, net (Tables)

12 Months Ended

Dec. 31, 2020

Intangible Assets, net [Abstract]

Definite-lived Intangible Assets

Set forth below is a detailed listing of definite-lived intangible assets as of:

	December 31,
	2020										2019
	Balance			Accumulated Amortization				Intangible assets, net			Intangible assets, net

Core technology		$	5,700		$	(3,135	)		$	2,565	$	3,135
Product technology			2,000			(2,000	)			-		200
Customer relationships			6,900			(3,795	)			3,105		3,795
Tradenames			1,500			(825	)			675		825
		$	16,100		$	(9,755	)		$	6,345	$	7,955

Finite-lived Intangible Assets Amortization Expense

Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:

2021	$	1,410
2022		1,410
2023		1,410
2024		1,410
2025		705
Total	$	6,345

Goodwill (Tables)

12 Months Ended

Dec. 31, 2020

Goodwill [Abstract]

Goodwill Information

The balance of goodwill at December 31, 2020, and 2019 consisted of the following:

Dermatology Recurring Procedures segment	$	7,958
Dermatology Procedures Equipment segment		845
Total	$	8,803

Other Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2020

Other Accrued Liabilities [Abstract]

Other Accrued Liabilities

Other Accrued Liabilities:

	December 31, 2020		December 31, 2019

Accrued warranty, current, see Note 1	$	87	$	170
Accrued compensation, including commissions and vacation		891		1,193
Accrued state sales use and other taxes		3,105		3,193
Accrued professional fees and other accrued liabilities		607		578
Total other accrued liabilities	$	4,690	$	5,134

Long-term Debt (Tables)

12 Months Ended

Dec. 31, 2020

Long-term Debt [Abstract]

Long-term Debt

The following summarizes the Company’s long term debt:

Term notes	$	2,528
Less: current portion		(1,478	)
Total long-term debt	$	1,050

Future Payments for Long-term Debt

The following table summarizes the future payments that the Company is obligated to make for long-term debt for the future period as to the stated terms of the loans:

2021	$	1,478
2022		568
2023		10
2024		10
2025		10
Thereafter		452
Total	$	2,528

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2020

Commitments and Contingencies [Abstract]

Operating Lease Maturities

The following table summarizes the Company’s operating lease maturities as of December 31, 2020:

For the year ending December 31,
2021	$	456
2022		371
2023		242
2024		186
Total remaining lease payments		1,255
Less: imputed interest		(176	)
Total lease liabilities	$	1,079

Stock-based compensation (Tables)

12 Months Ended

Dec. 31, 2020

Stock-based compensation [Abstract]

Stock Option Transactions

A summary of option transactions for all of the Company’s stock options during the years ended December 31, 2020, and 2019 follows:

	Number of Stock Options			Weighted Average Exercise Price
Outstanding at January 1, 2019		4,342,765		$	2.02
Granted		875,000			2.46
Exercised		(86,250	)		1.74
Expired/forfeited		(223,477	)		6.43
Outstanding at December 31, 2019		4,908,038			1.90
Granted		400,000			1.46
Exercised		(15,000	)		1.29
Expired/forfeited		(150	)		170.00
Outstanding at December 31, 2020		5,292,888		$	1.87
Exercisable at December 31, 2020		3,442,501		$	1.87
Options expected to vest at December 31, 2020		1,850,387		$	1.86

Stock Options Outstanding and Exercisable

The outstanding options at December 31, 2020, have a range of exercise prices and associated weighted remaining contractual life and weighted average exercise price, as follows:

Options Range of Exercise Prices		Outstanding Number of Shares		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Exercisable Number of Shares		Exercisable Weighted Average Exercise Price
$	1.11 - $2.00		4,185,877		7.59	$	1.47		2,918,323	$	1.43
$	2.01 - $5.00		941,000		8.67		2.52		358,267		2.61
$	5.01 - $181.00		166,011		4.54		8.07		165,911		8.03
Total			5,292,888		7.69	$	1.87		3,442,501	$	1.87

Fair Value of Each Option Award Granted

The fair value of each option award granted during the period is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

	Years Ended December 31,
	2020	2019
Risk-free interest rate	.53%	1.66%
Volatility	94%	71%
Expected dividend yield	0%	0%
Expected life	6.0 years	6.0 years

Unvested Stock Option Activity

The following table summarizes the Company’s unvested stock option activity:

	Options			Weighted Average Grant Date Fair Value
Unvested balance as of January 1, 2019		3,394,468		$	0.82
Granted		875,000			1.56
Vested		(1,265,956	)		0.78
Forfeited/expired		-			-
Unvested balance as of December 31, 2019		3,003,512		$	1.05
Granted		400,000			1.11
Vested		(1,553,125	)		0.96
Forfeited/expired		-			-
Unvested balance at December 31, 2020		1,850,387		$	1.15

Restricted Stock Unit Award

Restricted stock unit unvested are summarized in the following table:

	Number of restricted stock units			Weighted Average Grant Date Fair Value
Unvested balance at January 1, 2019		70,049		$	2.07
Granted		77,237			2.46
Vested/settled		(60,387	)		2.07
Forfeited/expired		(9,662	)		2.07
Unvested balance at December 31, 2019		77,237		$	2.46
Granted		-			-
Vested/settled		(68,091	)		2.46
Forfeited/expired		(9,146	)		2.46
Unvested balance at December 31, 2020		-		$	-

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Taxes [Abstract]

Components of Income Tax Expense (Benefit)

Income Taxes:

	Years Ended December 31,
	2020		2019
Current:
Federal	$	-	$	(58	)
State		21		20
		21		(38	)
Deferred:
Federal		129		(86	)
State		125		(25	)
		254		(111	)
Income tax expense (benefit)	$	275	$	(149	)

Computation of U.S. Federal Income Tax Rate to Pretax Loss from Continuing Operations

The difference between the actual income tax expense (benefit) and that computed by applying the U.S. federal income tax rate to pretax loss from continuing operations is summarized below:

	For the Years Ended December 31,
	2020				2019

Computed expected tax expense (benefit)		$	(869	)		$	(827	)
State tax (benefit)expense, net of federal effect			(272	)			(106	)
Other			221				377
Net increase (decrease) in valuation allowance			1,195				407
Provision for income taxes		$	275			$	(149	)

Tax Effects of Temporary Differences Impact on Deferred Tax Assets and Liabilities

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2020, and 2019 are as follows:

	December 31,
	2020			2019

Deferred tax assets/(liabilities):
Net operating loss carryforward	$	45,819		$	43,433
Intangible assets		1,450			2,046
Inventory		51			51
Reserves & accrued expenses		896			992
Property & equipment		(178	)		389
Non-cash compensation		808			850
Goodwill		(815	)		(667	)
Right of use asset		(249	)		(331	)
Lease liability		272			350
Total net deferred tax assets		48,054			47,113
Less: valuation allowance		(48,308	)		(47,113	)
Net deferred tax assets/(liabilities)	$	(254	)	$	-

Business Segments (Tables)

12 Months Ended

Dec. 31, 2020

Business Segments [Abstract]

Segment Reporting Information by Segment

The following tables reflect results of operations from our business segments for the periods indicated below:

Year Ended December 31, 2020

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues	$	17,409		$	5,681		$	23,090
Costs of revenues		5,832			3,124			8,956
Gross profit		11,577			2,557			14,134
Gross profit %		66.5	%		45.0	%		61.2	%

Allocated operating expenses:
Engineering and product development		1,101			173			1,274
Selling and marketing expenses		8,437			601			9,038
Unallocated operating expenses		-			-			7,898
		9,538			774			18,210
Income (loss) from operations		2,039			1,783			(4,076	)
Interest expense, net		-			-			(61	)
Income (loss) before income taxes	$	2,039		$	1,783		$	(4,137	)

Year Ended December 31, 2019

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues	$	23,713		$	7,873		$	31,586
Costs of revenues		7,033			4,283			11,316
Gross profit		16,680			3,590			20,270
Gross profit %		70.3	%		45.6	%		64.2	%

Allocated operating expenses:
Engineering and product development		845			157			1,002
Selling and marketing expenses		11,191			812			12,003
Unallocated operating expenses		-			-			10,275
		12,036			969			23,280
Income (loss) from operations		4,644			2,621			(3,010	)
Interest expense, net		-			-			(515	)
Loss on extinguishment of debt		-			-			(414	)
Income (loss) before income taxes	$	4,644		$	2,621		$	(3,939	)

Total Assets by Reportable Segment

As of December 31, 2020, and 2019, total assets by reportable segment were as follows:

	December 31,
Assets:	2020		2019
Dermatology Recurring Procedures	$	25,112	$	27,620
Dermatology Procedures Equipment		3,052		3,382
Other unallocated assets		18,614		16,341
Consolidated total	$	46,778	$	47,343

The Company, Background (Details) $ in Thousands	12 Months Ended
The Company, Background (Details) $ in Thousands	Dec. 31, 2020 USD ($) Systems
Finite-Lived Intangible Assets, Net [Abstract]
Delayed payments to vendors \| $	$ 678
XTRAC [Member] \| United States [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Number of systems placed in dermatologists offices	832
XTRAC [Member] \| International [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Number of systems placed in dermatologists offices	28

The Company, Revenue Recognition (Details) $ in Thousands	12 Months Ended
The Company, Revenue Recognition (Details) $ in Thousands	Dec. 31, 2020 USD ($) Arrangement	Dec. 31, 2019 USD ($)
Revenue Recognition [Abstract]
Number of types of arrangements \| Arrangement	2
Lease term	36 months
Lease automatic renewal period	1 year
Remaining performance obligations	$ 115	$ 324
Short-term contract liabilities	108	209
Long-term contract liabilities	7	115
Contract liabilities recognized as revenue	209	155
Revenue reimbursements	$ 485	779
Minimum [Member]
Revenue Recognition [Abstract]
Notice period to cancel contract agreement	30 days
Maximum [Member]
Revenue Recognition [Abstract]
Notice period to cancel contract agreement	60 days
South Korea [Member]
Revenue Recognition [Abstract]
Lease term	48 months
International [Member]
Revenue Recognition [Abstract]
Remaining performance obligations	$ 3,244
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue Recognition [Abstract]
Remaining performance obligations		$ 209
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue Recognition [Abstract]
Remaining performance obligations	$ 108
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 \| International [Member]
Revenue Recognition [Abstract]
Remaining performance obligations	$ 948
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue Recognition [Abstract]
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 \| International [Member]
Revenue Recognition [Abstract]
Remaining performance obligations	$ 954
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue Recognition [Abstract]
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| International [Member]
Revenue Recognition [Abstract]
Remaining performance obligations	$ 867
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue Recognition [Abstract]
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| International [Member]
Revenue Recognition [Abstract]
Remaining performance obligations	$ 440
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 \| International [Member]
Revenue Recognition [Abstract]
Remaining performance obligations	$ 35
Expected timing of satisfaction period	1 year

The Company, Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash and Cash Equivalents, at Carrying Value [Abstract]
Proceeds due from credit card transactions	$ 10	$ 21
Maximum [Member]
Cash and Cash Equivalents, at Carrying Value [Abstract]
Credit card transaction settlement term	5 days

The Company, Accounts Receivable, net (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accounts Receivable, net [Abstract]
Allowance for doubtful accounts	$ 274	$ 184

The Company, Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Inventories [Abstract]
Reserves on inventory	$ 225	$ 225

The Company, Property, Equipment and Depreciation (Details)	12 Months Ended
	Dec. 31, 2020
Excimer Lasers-in-Service [Member]
Property, Plant and Equipment, Net [Abstract]
Property, plant and equipment, useful life	5 years
Computer Hardware and Software [Member] \| Minimum [Member]
Property, Plant and Equipment, Net [Abstract]
Property, plant and equipment, useful life	3 years
Computer Hardware and Software [Member] \| Maximum [Member]
Property, Plant and Equipment, Net [Abstract]
Property, plant and equipment, useful life	7 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment, Net [Abstract]
Property, plant and equipment, useful life	3 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment, Net [Abstract]
Property, plant and equipment, useful life	7 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment, Net [Abstract]
Property, plant and equipment, useful life	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment, Net [Abstract]
Property, plant and equipment, useful life	7 years

The Company, Intangible Assets (Details)	12 Months Ended
The Company, Intangible Assets (Details)	Dec. 31, 2020
Minimum [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Estimated useful life	3 years
Maximum [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Estimated useful life	10 years

The Company, Accounting for the Impairment of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Accounting for the Impairment of Goodwill [Abstract]
Goodwill impairment	$ 0	$ 0

The Company, Accrued Warranty Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Product Warranty Accrual [Roll Forward]
Accrual at beginning of period	$ 232	$ 238
Additions charged to warranty expense	67	222
Expiring warranties/claims satisfied	(186)	(228)
Total	113	232
Less: current portion	(87)	(170)
Total long-term accrued warranty costs	$ 26	$ 62
Minimum [Member]
Product Warranty Liability [Line Items]
Standard warranty period	1 year
Offered warranty period	3 years
Maximum [Member]
Product Warranty Liability [Line Items]
Standard warranty period	2 years
Offered warranty period	4 years

The Company, Product Development Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Product Development Costs [Abstract]
Engineering and product development costs	$ 1,274	$ 1,002

The Company, Advertising Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Advertising Costs [Abstract]
Advertising expense	$ 697	$ 1,936

The Company, Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	5,523,326	5,881,396
Series C Convertible Preferred Stock [Member]
Loss per common share [Abstract]
Loss attributable to each class	$ (18)	$ (193)
Weighted average number of shares outstanding during the period (in shares)	368	4,577
Basic and diluted loss per share (in dollars per share)	$ (48.59)	$ (42.24)
Warrants [Member]
Loss per common share [Abstract]
Number of warrants to purchase common stock (in shares)			403,090
Common Stock [Member]
Loss per common share [Abstract]
Loss attributable to each class	$ (4,394)	$ (3,597)
Weighted average number of shares outstanding during the period (in shares)	33,609,922	31,978,665
Basic and diluted loss per share (in dollars per share)	$ (0.13)	$ (0.11)
Common Stock Purchase Warrants [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	434,791	1,517,528
Restricted Stock Units [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	131,247	128,417
Common Stock Options [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	4,957,288	4,235,451

The Company, Stock-Based Compensation (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Performance Awards [Member]
Stock-Based Compensation [Abstract]
Granted (in shares)	0	0

The Company, Accounting Pronouncements Recently Adopted (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accounting Pronouncements Recently Adopted [Abstract]
Right-of-use assets	$ 988	$ 1,314
Lease liabilities	$ 1,079
ASU 2016-02 [Member]
Accounting Pronouncements Recently Adopted [Abstract]
Right-of-use assets		848
Lease liabilities		$ 848

Revenue, Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Abstract]
Revenues, net	$ 23,090	$ 31,586
Dermatology Recurring Procedures [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	17,409	23,713
Dermatology Procedures Equipment [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	5,681	7,837
Domestic [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	17,804	24,888
Domestic [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	16,848	23,645
Domestic [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	956	1,243
Foreign [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	5,286	6,698
Foreign [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	561	68
Foreign [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	$ 4,725	$ 6,630

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenue, Future Fixed Payments from International Recurring Revenue Customers (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 115	$ 324
International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	3,244
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers		$ 209
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 108
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 948
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 954
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 867
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 440
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 35
Expected timing of satisfaction period	1 year

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of inventory [Abstract]
Raw materials and work in process	$ 2,949	$ 2,651
Finished goods	495	376
Inventories, net	$ 3,444	$ 3,027

Property and Equipment, net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 23,374	$ 21,331
Accumulated depreciation and amortization	(17,845)	(15,962)
Property and equipment, net	5,529	5,369
Depreciation and related amortization expense	1,975	2,693
Lasers Placed-In-Service [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	22,942	20,925
Equipment, Computer Hardware and Software [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	146	146
Furniture and Fixtures [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	243	234
Leasehold Improvements [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 43	$ 26

Intangible Assets, net (Details) - USD ($) $ in Thousands	12 Months Ended
Intangible Assets, net (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets, Net [Abstract]
Balance	$ 16,100
Accumulated amortization	(9,755)	$ 8,145
Intangible assets, net	6,345	7,955
Amortization expense of intangible assets	1,610	1,810
Estimated amortization expense [Abstract]
2021	1,410
2022	1,410
2023	1,410
2024	1,410
2025	705
Intangible assets, net	$ 6,345	7,955
Minimum [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Estimated useful life	3 years
Maximum [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Estimated useful life	10 years
Core Technology [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	$ 5,700
Accumulated amortization	(3,135)
Intangible assets, net	2,565	3,135
Estimated amortization expense [Abstract]
Intangible assets, net	2,565	3,135
Product Technology [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	2,000
Accumulated amortization	(2,000)
Intangible assets, net	0	200
Estimated amortization expense [Abstract]
Intangible assets, net	0	200
Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	6,900
Accumulated amortization	(3,795)
Intangible assets, net	3,105	3,795
Estimated amortization expense [Abstract]
Intangible assets, net	3,105	3,795
Tradenames [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	1,500
Accumulated amortization	(825)
Intangible assets, net	675	825
Estimated amortization expense [Abstract]
Intangible assets, net	$ 675	$ 825

Goodwill (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Goodwill by Segments [Abstract]
Goodwill	$ 8,803	$ 8,803
Impairment of goodwill	0	0
Dermatology Recurring Procedures [Member]
Goodwill by Segments [Abstract]
Goodwill	7,958	7,958
Dermatology Procedures Equipment [Member]
Goodwill by Segments [Abstract]
Goodwill	$ 845	$ 845

Other Accrued Liabilities (Details) $ in Thousands	1 Months Ended	12 Months Ended
Other Accrued Liabilities (Details) $ in Thousands	Jan. 31, 2021	Dec. 31, 2020 USD ($) Assessment	Dec. 31, 2019 USD ($)
Other Accrued Liabilities [Abstract]
Accrued warranty, current, see Note 1		$ 87	$ 170
Accrued compensation, including commissions and vacation		891	1,193
Accrued state sales, use and other taxes		3,105	3,193
Accrued professional fees and other accrued liabilities		607	578
Total other accrued liabilities		4,690	$ 5,134
Income Tax Examination, Penalties and Interest Accrued [Abstract]
Interest amount		$ 171
Subsequent Event [Member]
Income Tax Examination, Penalties and Interest Accrued [Abstract]
Notice period to file an appeal	30 days
Tax Period from March 2014 through February 2020 [Member]
Income Tax Examination, Penalties and Interest Accrued [Abstract]
Number of assessments \| Assessment		2
Estimated tax positions subject to audit		$ 1,484
Tax Period from June 2015 through March 2018 [Member]
Income Tax Examination, Penalties and Interest Accrued [Abstract]
Assessment amount		$ 720

Note Payable (Details) - USD ($) $ in Thousands	12 Months Ended
Note Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 30, 2020	Dec. 31, 2019	Dec. 30, 2019
Note [Member]
Debt Instruments [Abstract]
Face amount of debt				$ 7,275
Debt instrument term	1 year
Maturity date	Dec. 30, 2021
Fixed interest rate		1.40%	2.79%
Time Deposit [Member]
Debt Instruments [Abstract]
Fixed interest rate		0.40%	1.79%

Long-term Debt (Details) $ in Thousands					12 Months Ended
Long-term Debt (Details) $ in Thousands	May 22, 2020 USD ($)	May 29, 2018 USD ($)	Jan. 29, 2016 USD ($)	Dec. 30, 2015 USD ($) Tranche	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Apr. 22, 2020 USD ($)
Long-term Debt [Abstract]
Loss on extinguishment of debt					$ 0	$ (414)
Term notes					2,528
Less: current portion					(1,478)	0
Total long-term debt					1,050	$ 0
Future Payments for Long-Term Debt [Abstract]
2021					1,478
2022					568
2023					10
2024					10
2025					10
Thereafter					452
Term notes					$ 2,528
PPP Loans [Member]
Long-term Debt [Abstract]
Maturity date					May 01, 2022
Face amount of debt							$ 2,028
Interest rate percentage							1.00%
Debt instrument term					2 years
Debt instrument, extended term					5 years
Percentage of loan proceeds submitted for forgiveness to the SBA					100.00%
Balance amount of loan					$ 2,028
EDIL [Member]
Long-term Debt [Abstract]
Face amount of debt	$ 500
Interest rate percentage	3.75%
Debt instrument term					30 years
Balance amount of loan					$ 500
Installment monthly payment amount	$ 2
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member]
Long-term Debt [Abstract]
Maximum borrowing capacity under the agreement				$ 12,000
Number of tranches \| Tranche				2
Repayment of debt		$ (3,000)
Maturity date					May 31, 2022
Credit facility amount outstanding		$ 10,571
Period without debt principal payments due					18 months
Monthly payment, principal					$ 252
Percentage of change in cash flows, due to debt modifications		10.00%
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| LIBOR [Member]
Long-term Debt [Abstract]
Debt instrument term of variable rate				1 month	1 month
Basis spread on variable rate				8.25%	7.25%
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| First Tranche [Member]
Long-term Debt [Abstract]
Proceeds from credit facility				$ 10,500
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| Second Tranche [Member]
Long-term Debt [Abstract]
Proceeds from credit facility			$ 1,500

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Lessee, Operating Lease, Description [Abstract]
Operating lease costs	$ 448	$ 448
Cash paid for amounts included in measurement of operating lease liabilities	$ 436	$ 371
Incremental borrowing rate	9.76%	9.76%
Weighted average remaining lease term	3 years 1 month 6 days	4 years 1 month 6 days
Operating Lease Maturities [Abstract]
2021	$ 456
2022	371
2023	242
2024	186
Total remaining lease payments	1,255
Less: imputed interest	(176)
Total lease liabilities	$ 1,079
Minimum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term	1 year
Maximum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term	4 years
Facility One [Member]
Lessee, Operating Lease, Description [Abstract]
Renewal option term	2 years
Carlsbad Facility [Member]
Lessee, Operating Lease, Description [Abstract]
Renewal option term	5 years

Warrants (Details) - Warrants [Member]	Dec. 31, 2020 $ / shares shares
Warrants and Rights [Abstract]
Number of shares underlying warrants (in shares) \| shares	403,090
Exercise price of warrants (in dollars per share) \| $ / shares	$ 3.75

Stockholders' Equity, Preferred Stock and Common Stock (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class of Stock Disclosures [Abstract]
Series C Convertible Preferred Stock, shares authorized (in shares)	10,000,000	10,000,000
Series C Convertible Preferred Stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, stated value (in dollars per share)	$ 1,000
Series C Convertible Preferred Stock, shares issued (in shares)	0	2,103
Series C Convertible Preferred Stock, shares outstanding (in shares)	0	2,103
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock shares issued on exercise of options (in shares)	33,801,045	32,932,273
Common stock, shares outstanding (in shares)	33,801,045	32,932,273
Series C Convertible Preferred Shares [Member]
Class of Stock Disclosures [Abstract]
Beneficial ownership percentage	9.99%
Preferred stock conversion price (in dollars per share)	$ 2.69
Number of common shares issuable on conversion of preferred stock (in shares)	15,049,000
Number of common shares issued on conversion of preferred stock (in shares)	782,089	2,923,791

Stockholders' Equity, Outstanding Common Stock Warrants (Details) - Expiration Date, January 29, 2021 [Member]	12 Months Ended
	Dec. 31, 2020 $ / shares shares
Warrants and Rights [Abstract]
Warrants outstanding (in shares) \| shares	19,812
Exercise price (in dollars per share) \| $ / shares	$ 5.30
Expiration date	Jan. 29, 2021

Stock-based compensation, Stock Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	May 29, 2018	Oct. 27, 2016
Stock Options [Member]
Number of Stock Options [Abstract]
Outstanding at beginning period (in shares)	4,908,038	4,342,765
Granted (in shares)	400,000	875,000
Exercised (in shares)	(15,000)	(86,250)
Expired/forfeited (in shares)	(150)	(223,477)
Outstanding at end of period (in shares)	5,292,888	4,908,038
Exercisable at end of period (in shares)	3,442,501
Options expected to vest at end of period (in shares)	1,850,387
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 1.90	$ 2.02
Granted (in dollars per share)	1.46	2.46
Exercised (in dollars per share)	1.29	1.74
Expired/forfeited (in dollars per share)	170.00	6.43
Outstanding at end of period (in dollars per share)	1.87	$ 1.90
Exercisable at end of period (in dollars per share)	1.87
Options expected to vest at end of period (in dollars per share)	$ 1.86
Stock Incentive Plan 2016 [Member]
Stock Options [Abstract]
Number of shares available for issuance (in shares)	41,774		3,134,365	2,058,880

Stock-based compensation, Stock Options Plan by Exercise Price Range (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Abstract]
Outstanding number of shares (in shares)	5,292,888
Weighted average remaining contractual life	7 years 8 months 8 days
Weighted average exercise price (in dollars per share)	$ 1.87
Exercisable number of shares (in shares)	3,442,501
Exercisable weighted average exercise price (in dollars per share)	$ 1.87
Weighted average remaining contractual life of exercisable stock options	7 years 3 months 18 days	8 years 11 days
$1.11 - $2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Abstract]
Option range of exercise prices, lower range limit (in dollars per share)	$ 1.11
Option range of exercise prices, upper range limit (in dollars per share)	$ 2.00
Outstanding number of shares (in shares)	4,185,877
Weighted average remaining contractual life	7 years 7 months 2 days
Weighted average exercise price (in dollars per share)	$ 1.47
Exercisable number of shares (in shares)	2,918,323
Exercisable weighted average exercise price (in dollars per share)	$ 1.43
$2.01 - $5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Abstract]
Option range of exercise prices, lower range limit (in dollars per share)	2.01
Option range of exercise prices, upper range limit (in dollars per share)	$ 5.00
Outstanding number of shares (in shares)	941,000
Weighted average remaining contractual life	8 years 8 months 1 day
Weighted average exercise price (in dollars per share)	$ 2.52
Exercisable number of shares (in shares)	358,267
Exercisable weighted average exercise price (in dollars per share)	$ 2.61
$5.01 - $181.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Abstract]
Option range of exercise prices, lower range limit (in dollars per share)	5.01
Option range of exercise prices, upper range limit (in dollars per share)	$ 181.00
Outstanding number of shares (in shares)	166,011
Weighted average remaining contractual life	4 years 6 months 14 days
Weighted average exercise price (in dollars per share)	$ 8.07
Exercisable number of shares (in shares)	165,911
Exercisable weighted average exercise price (in dollars per share)	$ 8.03

Stock-based compensation, Fair Value Assumptions (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Nov. 13, 2020	Nov. 21, 2019	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate			0.53%	1.66%
Volatility			94.00%	71.00%
Expected dividend yield			0.00%	0.00%
Expected life			6 years	6 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Share price (in dollars per share)			$ 1.50	$ 2.08
Aggregate intrinsic value of options outstanding			$ 611	$ 2,300
Aggregate intrinsic value of options exercisable			546	$ 1,156
Intrinsic value of options exercised			$ 3
Issuance of common stock (in shares)			400,000	875,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Exercised (in shares)			(15,000)	(86,250)
Weighted average exercise price (in dollars per share)			$ 1.29	$ 1.74
Stock option exercise, stock issued (in shares)				36,410
Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Expiry period of option			10 years
Stock Options [Member] \| November 13, 2020 [Member] \| Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Expiry period of option			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)	150,000
Purchase price (in dollars per share)	$ 1.46
Term of vesting			3 years
Aggregate fair value of shares issued	$ 443
Stock Options [Member] \| November 13, 2020 [Member] \| Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Expiry period of option			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)	250,000
Purchase price (in dollars per share)	$ 1.46
Term of vesting			3 years
Aggregate fair value of shares issued	$ 443
Stock Options [Member] \| November 21, 2019 [Member] \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Expiry period of option			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)		300,000
Purchase price (in dollars per share)		$ 2.46
Term of vesting			3 years
Aggregate fair value of shares issued		$ 1,361
Stock Options [Member] \| November 21, 2019 [Member] \| Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Expiry period of option			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)		150,000
Purchase price (in dollars per share)		$ 2.46
Term of vesting			3 years
Aggregate fair value of shares issued		$ 1,361
Stock Options [Member] \| November 21, 2019 [Member] \| Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Expiry period of option			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)		425,000
Purchase price (in dollars per share)		$ 2.46
Term of vesting			3 years
Aggregate fair value of shares issued		$ 1,361
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Issuance of common stock (in shares)			0	0

Stock-based compensation, Unvested Stock Option Activity (Details) - Stock Options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Options [Roll Forward]
Unvested balance at beginning of period (in shares)	3,003,512	3,394,468
Granted (in shares)	400,000	875,000
Vested (in shares)	(1,553,125)	(1,265,956)
Forfeited/expired (in shares)	0	0
Unvested balance at end of period (in shares)	1,850,387	3,003,512
Weighted Average Grant Date Fair Value [Abstract]
Unvested balance at beginning of period (in dollars per share)	$ 1.05	$ 0.82
Granted (in dollars per share)	1.11	1.56
Vested (in dollars per share)	0.96	0.78
Forfeited/expired (in dollars per share)	0	0
Unvested balance at end of period (in dollars per share)	$ 1.15	$ 1.05

Stock-based compensation, Restricted Stock Units (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Nov. 21, 2019	Dec. 31, 2020	Dec. 31, 2019
Weighted Average Grant Date Fair Value [Abstract]
Stock-based compensation expense		$ 1,633	$ 1,195
Unrecognized compensation expense		$ 1,715
Weighted average period of recognition		1 year 18 days
Restricted Stock Units [Member]
Restricted Stock Units [Abstract]
Unvested balance at beginning of period (in shares)		77,237	70,049
Granted (in shares)		0	77,237
Vested/settled (in shares)		(68,091)	(60,387)
Forfeited/expired (in shares)		(9,146)	(9,662)
Unvested balance at end of period (in shares)		0	77,237
Weighted Average Grant Date Fair Value [Abstract]
Unvested balance at beginning of period (in dollars per share)		$ 2.46	$ 2.07
Granted (in dollars per share)		0	2.46
Vested/settled (in dollars per share)		2.46	2.07
Forfeited/expired (in dollars per share)		2.46	2.07
Unvested balance at end of period (in dollars per share)		$ 0	$ 2.46
Number of shares vested but not issued (in shares)		88,194	91,787
Restricted Stock Units [Member] \| Members of the Board of Directors [Member]
Restricted Stock Units [Abstract]
Aggregate grant date fair value	$ 190	$ 290
Term of vesting	12 months	12 months
Granted (in shares)	77,237	140,097
Weighted Average Grant Date Fair Value [Abstract]
Granted (in dollars per share)	$ 2.46	$ 2.07

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current [Abstract]
Federal	$ 0	$ (58)
State	21	20
Current income tax	21	(38)
Deferred [Abstract]
Federal	129	(86)
State	125	(25)
Deferred income tax	254	(111)
Income tax expense (benefit)	275	(149)
Difference between income tax benefit and U.S. federal income tax rate to pretax loss from continuing operations [Abstract]
Computed expected tax expense (benefit)	(869)	(827)
State tax (benefit)expense, net of federal effect	(272)	(106)
Other	221	377
Net increase (decrease) in valuation allowance	1,195	407
Income tax expense (benefit)	$ 275	$ (149)
Federal corporate tax rate	21.00%	21.00%
Deferred tax assets/(liabilities) [Abstract]
Net operating loss carryforward	$ 45,819	$ 43,433
Intangible assets	1,450	2,046
Inventory	51	51
Reserves & accrued expenses	896	992
Property & equipment	(178)
Property & equipment		389
Non-cash compensation	808	850
Goodwill	(815)	(667)
Right of use asset	(249)	(331)
Lease liability	272	350
Total net deferred tax assets	48,054	47,113
Less: valuation allowance	(48,308)	(47,113)
Net deferred tax assets/(liabilities)	(254)	0
Valuation allowance - Deferred tax asset change in amount	1,195	407
Federal operating loss carryforwards, net	$ 200,976	$ 200,976
Earliest open tax year subject to examination	2016

Business Segments (Details) $ in Thousands	12 Months Ended
Business Segments (Details) $ in Thousands	Dec. 31, 2020 USD ($) Segment	Dec. 31, 2019 USD ($)
Business Segments [Abstract]
Number of operating segments \| Segment	2
Results of Operations from Business Segments [Abstract]
Revenues	$ 23,090	$ 31,586
Cost of revenues	8,956	11,316
Gross profit	$ 14,134	$ 20,270
Gross profit %	61.20%	64.20%
Allocated operating expenses [Abstract]
Engineering and product development	$ 1,274	$ 1,002
Selling and marketing expenses	9,038	12,003
Unallocated operating expenses	7,898	10,275
Total operating expenses	18,210	23,280
Income (loss) from operations	(4,076)	(3,010)
Interest expense, net	(61)	(515)
Loss on extinguishment of debt	0	(414)
Income (loss) before income taxes	(4,137)	(3,939)
Assets	46,778	47,343
Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	17,409	23,713
Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	5,681	7,837
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	17,409	23,713
Cost of revenues	5,832	7,033
Gross profit	$ 11,577	$ 16,680
Gross profit %	66.50%	70.30%
Allocated operating expenses [Abstract]
Engineering and product development	$ 1,101	$ 845
Selling and marketing expenses	8,437	11,191
Unallocated operating expenses	0	0
Total operating expenses	9,538	12,036
Income (loss) from operations	2,039	4,644
Interest expense, net	0	0
Loss on extinguishment of debt		0
Income (loss) before income taxes	2,039	4,644
Assets	25,112	27,620
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	5,681	7,873
Cost of revenues	3,124	4,283
Gross profit	$ 2,557	$ 3,590
Gross profit %	45.00%	45.60%
Allocated operating expenses [Abstract]
Engineering and product development	$ 173	$ 157
Selling and marketing expenses	601	812
Unallocated operating expenses	0	0
Total operating expenses	774	969
Income (loss) from operations	1,783	2,621
Interest expense, net	0	0
Loss on extinguishment of debt		0
Income (loss) before income taxes	1,783	2,621
Assets	3,052	3,382
Other Unallocated Assets [Member]
Allocated operating expenses [Abstract]
Assets	$ 18,614	$ 16,341

Related Parties (Details) $ in Thousands	12 Months Ended
Related Parties (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Accelmed Growth Partners L.P. [Member]
Related Party Transaction [Abstract]
Indemnification cost reimbursed	$ 25

Significant Customer Concentration (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Concentration Risk Percentage [Abstract]
Revenues, net	$ 23,090	$ 31,586
Revenue [Member] \| Customer Concentration Risk [Member]
Concentration Risk Percentage [Abstract]
Revenues, net	$ 2,679	$ 6,133
Concentration risk percentage	11.60%	19.40%
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Concentration Risk Percentage [Abstract]
Accounts receivable		$ 661
Concentration risk percentage		15.10%

- Definition

+ References

+ Details

Employee 401(k) Savings Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employee 401(k) Savings Plan [Abstract]
Employer contribution amount	$ 240	$ 248

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands					12 Months Ended
	Mar. 01, 2021	Feb. 28, 2021	Feb. 24, 2021	Jan. 29, 2021	Dec. 31, 2020	Dec. 31, 2019
Stock Options [Member]
Subsequent Events [Abstract]
Granted (in shares)					400,000	875,000
Strike price (in dollars per share)					$ 1.11	$ 1.56
Subsequent Event [Member]
Subsequent Events [Abstract]
Number of warrants expired (in shares)				19,812
Subsequent Event [Member] \| Incoming Chief Executive Officer [Member] \| Stock Options [Member]
Subsequent Events [Abstract]
Granted (in shares)	1,632,590
Strike price (in dollars per share)	$ 1.73
Award vesting period	3 years
Subsequent Event [Member] \| Incoming Chief Executive Officer [Member] \| Stock Options [Member] \| Vesting on First Anniversary of Date of Grant [Member]
Subsequent Events [Abstract]
Granted (in shares)	544,198
Subsequent Event [Member] \| Incoming Chief Executive Officer [Member] \| Stock Options [Member] \| Vesting Every Three Months Thereafter [Member]
Subsequent Events [Abstract]
Granted (in shares)	136,049
Subsequent Event [Member] \| Separation Agreement [Member] \| Dr. Dolev Rafaeli [Member]
Subsequent Events [Abstract]
Period of lump sum payment for accrued but unused vacation days			84 days
Subsequent Event [Member] \| Separation Agreement [Member] \| Dr. Dolev Rafaeli [Member] \| Maximum [Member]
Subsequent Events [Abstract]
Reimbursement period of COBRA premium payments			18 months
Reimbursement amount to be paid for attorneys' fees			$ 10,000
Subsequent Event [Member] \| Separation Agreement [Member] \| Dr. Dolev Rafaeli [Member] \| Stock Options [Member]
Subsequent Events [Abstract]
Number of shares with accelerated vesting (in shares)		800,886